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Abstract 
 
Matrix metalloproteinases (MMPs) form an enzyme family capable of degrading almost all 
extracellular matrix (ECM) and basement membrane (BM) components. They play an important 
role in normal tissue remodelling and growth, as well as in many destructive pathological 
conditions such as inflammation, tumour growth and metastasis.  
 
The expression of MMP-8 in cultured human mature pulpal cells and odontoblasts was evaluated 
with polymerase chain reaction-method (PCR). Mesenchyme-derived cells, pulp tissue cells and 
odontoblasts expressed MMP-8, which was down-regulated by transforming growth factor ? 
(TGF-?) in these cell cultures. Immunohistochemical staining revealed MMP-8 protein in the 
odontoblasts. These results suggest that MMP-8 may participate in dentin matrix organization 
during dentin formation. 
The presence of MMP-8 in inflammatory pulpal and periapical tissues and in root-canal exudate 
during root-canal treatment was further studied. Using immunohistochemistry, MMP-8 staining 
was detected in polymorphonuclear leukocytes (PMNs), macrophages and plasma cells in both 
pulpal and periapical lesions. MMP-8 has evidently a role in pulpal and periapical inflammation. 
MMP-8 levels in periapical exudate were significantly reduced during root canal treatment. 
Measuring MMP-8 levels in periapical exudate may be used as a biochemical indicator/ 
molecular marker to monitor the inflammatory activity and success in root canal treatment.  
 
Odontogenic keratocyst (KC) has special characteristics; its epithelium proliferates rapidly and 
detaches easily from connective tissue stroma, it recurs easily and forms daughter cysts. With this 
background, the differential expression of MMPs in odontogenic cysts was studied. The results 
revealed colocalization of MMP-2 and MMP-13 with laminin-5 (Ln-5) ?2-chain in the KC 
basement membrane zone indicating that especially these MMPs may be responsible for the 
epithelial detachment of KC. 
In all odontogenic cysts, MMP-8 protein was detected not only in PMNs, but also macrophages 
and plasma cells by immunohistochemistry. In situ hybridization showed MMP-8 mRNA 
expression in the plasma cells of follicular cyst (FC). MMP-13 expression was also localized to 
plasma cells in periapical lesions, KCs and plasmacytoma (PLC) specimens by both 
immunohistochemical staining and in situ hybridization.  
Cultured multiple myeloma cells showed that the expression of MMP-8 and MMP-13 was 
enhanced by phorphol-12-myristate-13-acetate (PMA) and heparin combined with different 
cytokines like interleukin-6 (IL-6). 
 
Overall, these results show that MMPs play an important role in ECM and BM remodelling and 
destruction during dentin formation, inflammatory processes of pulpitis, apical periodontitis, and 
enlargement of odontogenic jaw cysts, as well as reflect the special characteristics of them.  
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1. Introduction 
 
 
MMPs form a group of proteases able to degrade most ECM and BM components (Kähäri and 
Saarialho-Kere 1999). MMPs are divided according to their substrate specificities and structures 
to interstitial collagenases, gelatinases, membrane-type MMPs, stromelysins, matrilysins and 
other MMPs. MMPs are important in physiological growth and tissue remodelling. Their role in 
tissue destructive pathological conditions is evident but still however not completely clarified. 
MMP expression is regulated by proinflammatory cytokines and growth factors as well as ECM 
components. The collagenases include MMP-1 (collagenase-1), MMP-8 (collagenase-2) and 
MMP-13 (collagenase-3), and the gelatinases (type IV collagenases) include MMP-2 (gelatinase 
A) and MMP-9 (gelatinase B). Collagenases and gelatinases, being able to break collagens and 
laminins, are considered to be the key MMPs responsible for ECM and BM destruction in many 
pathological conditions. (Vu and Werb 2000, Sternlicht and Werb 2001). 
 
MMPs have recently been found also in pulpal tissue and odontoblasts, where they play a role in 
dentin matrix formation and modulation during caries progression and secondary dentin 
formation (Llano et al 1997, Tjäderhane et al 1998). The role of MMPs in pulpal and periapical 
inflammation is still unclear.   
In order to expand odontogenic cysts need to destroy the surrounding bone and other tissues. 
MMPs take part in these tissue destructive cascades. Gelatinases and collagenases have been 
found in jaw cyst fluids and tissues (Teronen et al 1995a, b). KCs exert special characteristics 
(epithelial detachment and high recurrence rate) among the odontogenic jaw cysts. The reasons 
for these special qualities of the KC are not yet clarified (Neville et al 2002). Solitary bone PLC 
and multiple myeloma (MM) are malignant destructive pathological conditions of the bone. They 
are caused by pathologically growing plasma cells of monoclonal origin (Neville et al 2002). 
MM cells express gelatinases and MMP-1 and their expression is up-regulated during the active 
phase of MM disease (Vacca et al 1999, Ria et al 2002).  
 
In this investigation, the in vivo expression of collagenase MMP-8 in pulpal and periapical tissue 
was studied. The expression of collagenases, MMP-8 and MMP-13 and gelatinases, MMP-2 and 
MMP-9, was further studied in odontogenic cysts and plasmacytomas. The in vitro expression of 
MMP-8 in odontoblasts and MMP-8 and -13 in malignant plasma cell cultures activated by PMA, 
heparin and different cytokines was also studied. In addition, the expression of MMP-2, -8, -13 
and Ln-5 in the epithelium of KCs was investigated. The methods used were cell culture, in situ 
hybridization, immunohistochemisty, Western blot, Southern blot, immunofluorometric assay 
and PCR-analysis. 
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     2. Review of the Literature 
 
 
2.1 Dental pulp  
 
The pulpal tissue is mainly composed of cells, loose connective tissue and ground substance. The 
main cellular components are fibroblasts, odontoblasts, undifferentiated cells and defence cells. 
Major extracellular components are mature and immature collagen fibres, mainly collagen I and 
III, produced by pulpal fibroblasts and odontoblasts. The connective tissue of the pulp lacks 
elastic fibres. The ground substance in the pulp consists of hyaluronic acid, chondroitin sulphate, 
glycoproteins, carbohydrates and water. The pulp organ is well vascularised and contains nerve 
bundles. From its periphery to centre the pulp consists histologically of the odontoblast layer, 
cell-free zone of Weil, cell-rich zone, and pulp core (Fig. 1). The relations of these different 
zones vary depending on the age of the pulp. (Okiji 2002).  
 
2.1.1 Odontoblasts 
 
Odontoblasts, next to fibroblasts, are the second most prominent cells in the pulp tissue. The 
odontoblast cell processes extend to dentinal tubules while the odontoblast body is adjacent to the 
predentin in the pulp (Fig.1). The odontoblast location is called the odontogenic zone of the pulp. 
In the odontoblastic row, the cells lie close to each other and the adjacent cells are connected by 
three types of intercellular junctions: impermeable (tight), adhering and communicating (gap) 
junctions. A capillary network surrounds the odontoblasts. Odontoblasts are highly differentiated 
mesenchymal cells incapable of proliferating and their main function is to produce dentin. The 
cell body is responsible of the synthesis of matrix glycoproteins, collagens and ground substance, 
while the odontoblastic process that extends into the dentinal tubules is the secretory organ (Fig. 
1). (Okiji 2002). 
 
The main collagen produced by odontoblasts is collagen I, but they also produce type III collagen 
mRNA (Lukinmaa et al 1992, 1993), and cultured odontoblasts secrete type I and III collagen 
(Tjäderhane et al 2001). In addition to tissue-building-components odontoblasts express tissue 
destructive enzymes, MMPs, indicating a role for MMPs in the dentin organic matrix remodelling 
(Tjäderhane et al 1998, 2001). They secrete at least gelatinase-A (MMP-2), gelatinase-B (MMP-
9), collagenase-2 (MMP-8), collagenase-3 (MMP-13), enamelysin (MMP-20) and membrane 
type matrix metalloproteinase-1 (MT1-MMP) (Tjäderhane et al 2001, Palosaari et al 2002). 
MMPs can contribute to the dentin matrix modulation in the reparative dentin production and in 
caries progression (Tjäderhane et al 2001).   
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Figure 1. Odontoblasts in the predentin-pulp zone.  
Odontoblasts lie partly bedded inthe dentin in the odontogenic zone. The cell-free zone and the 
cell-rich zone are located in the pulp area. 
 (Modified from Walton and Torabinejad 1996) 
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2.2 Pulpal and periapical pathology and treatment 
 
Irritation and injury of pulpal tissues leads to inflammation called pulpitis. Untreated pulpitis may 
lead to pulp necrosis and, associated with the root canal infection finally lead to apical 
periodontitis, destruction of the bone surrounding the root apex of the affected tooth. If the apical 
inflammation is not eliminated it can cause more severe conditions, such as apical abscesses, 
radicular cysts and osteomyelitis. (Neville et al 2002). 
 
2.2.1 Pulpitis 
 
Pulpal inflammation is caused by microbes, and mechanical or chemical irritants.  
The pulp tissue injury causes cellular damage and the release of nonspecific proinflammatory 
mediators e.g., histamine, bradykinin, neurokinins, neuropeptides and prostaglandins. These 
factors cause vasodilatation, increased blood flow, exudate formation and edema. Rigid walls 
surround the pulp and the lack of lymphatic vessels can lead to arterial compression and tissue 
necrosis due to the pressure caused by inflammatory edema. The pulpal inflammation usually 
progresses slowly. Blood stasis leads to increased red blood cell aggregation, blood viscosity and 
CO2 levels, as well as decreased pH levels and waste product removal. (Walton and Torabinejad 
1996, Fouad 2002). Carious enamel and dentin contain numerous bacteria capable of eliciting 
inflammatory reactions in pulp. These reactions are not often caused by direct exposure to 
bacteria, but instead to their virulence factors or their toxins that penetrate via dentinal tubules 
into the pulp (Walton and Torabinejad 1996).  
 
The pulpal pathology may range from local inflammation (reversible pulpitis) to irreversible 
pulpitis, which can proceed to total root canal necrosis.  Chronic hyperplastic pulpitis (pulp 
polyp) is a unique pattern of pulpal inflammation occurring in young adults and children who 
have large exposure of pulp with even the entire dentinal roof missing. Reversible pulpitis is 
characterized by hyperemia, increased permeability of blood vessels (Takahashi 1990) and edema 
in the pulp, as well as chronic inflammatory infiltrate underlying the affected dentinal tubules. 
Clinical manifestations show mild-to-moderate pain of short duration. Different stimuli (cold, 
hot, sweet and sour) activate the pain that usually disappears when the stimulus is not present. 
Mobility and sensitivity to percussion are mostly absent. (Walton and Torabinejad 1996, Neville 
et al 2002). Irreversible pulpitis is usually sequela of reversible pulpitis associated with a higher 
level of inflammation at a stage where recovery is impossible. Histologically irreversible pulpitis 
often shows a crush in the venules resulting in focal necrosis. PMN cells and histiocytes 
dominate in these necrotic areas. It is worth noting that, irreversible pulpitis may process without 
any symptoms. If pain is present it may be spontaneous or continuous. In early irreversible 
pulpitis the sharp and severe pain continues even after stimuli are removed. In the early stage of 
pulpitis the tooth responds to the pulp vitality testing at lower levels and in the later inflammatory 
stage at higher levels or not at all. In the later stages of irreversible pulpitis, the pain becomes 
constant and very intense; however, cold may produce relief by causing vasoconstriction and a 
drop of pulpal pressure. The percussion sensitivity and mobility may be absent because the 
inflammation has not yet spread outside the tooth apex. (Walton and Torabinejad 1996, Neville et 
al 2002).  
 
The bacterial antigens and lipopolysaccharides (LPS) in the infected pulp increase the levels of 
immunoglobulins, prostaglandins and other proinflammatory mediators (Nakanishi et al 1995). In 
pulpal reaction, the bacterial components and inflammatory factors can stimulate the neutrophil 
degranulation and secretion by monocytes/macrophages (Morand et al 1981, McClanahan et al 
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1991, Cootauco et al 1993, Panagakos et al 1996, O’Boskey and Panagakos 1998, Chang et al 
2001, Lu et al 2002). The released IL-1 and tumour necrosis factor-? (TNF-?) are able to induce 
MMP-1, MMP-2 and the tissue inhibitor of metalloproteinases-1 (TIMP-1) gene expression in 
pulpal cells (Chang et al 2001, Lin et al 2001). Stimulation by black-pigmented Bacteroides 
elevates MMP-2 production (Chang et al 2002), and anaerobic bacterial extracts provoke pulp 
cells to excrete MMP-1 and MMP-2 as well as TIMP-1 (Nakata et al 2000). The levels of MMP-
1, -2 and -3 are statistically significantly higher in acute pulpitis than in normal pulp tissue (Shin 
et al 2002). The treatment of pulpitis varies from the removal of the local irritant, pulp capping to 
pulpectomy and root canal treatment or even extraction of the tooth depending on the severity of 
pulpitis. 
 
2.2.2 Apical periodontitis   
 
If pulpitis remains untreated and bacteria invade the pulp cavum and pulpal tissue it finally leads 
to apical periodontitis, which represents a protective and destructive inflammatory reaction also 
involving the bone surrounding the tooth apex. The infection in root canal is usually a mixed 
infection with anaerobic domination (Haapasalo 1989). 
In acute apical periodontitis (AAP), the pulp may be irreversibly inflamed or necrotic and it 
contains PMNs and monocyte/macrophages-like cells within a localized area at the apex. The 
bone and root resorption is not yet extensive enough to be detected in radiographs.  If not treated 
AAP develops into chronic apical periodontitis (CAP, periapical granuloma) leading to pulp 
necrosis and bacterial toxins invading into the apical zone. The host defence responds to these 
bacterial root canal exudates and a defensive granulation zone is formed. If the bacteria persists in 
the root canal and, despite the defence responses, invade outside the root apex, the lesion may 
progress into an abscess with or without fistulation. (Neville et al 2002). 
 
Histologically CAP is made up of inflamed granulation tissue surrounded by a fibrous connective 
tissue wall. CAP is most often infiltrated by lymphocytes, plasma cells, monocytes/macrophages, 
as well as PMNs, and less frequently, mast cells, eosinophils and foam cells. (Neville et al 2002). 
A collection of Russell bodies, scattered eosinophilic globules of gammaglobulins, may be seen if 
numerous plasma cells are present, as well as lightly basophilic particles (pyronine bodies). These 
plasma cell products may be found in any accumulation of plasma cells and are not specific for 
CAP. Cholesterol clefts associated with multinucleated foreign body giant cells and red blood cell 
areas with hemosiderin pigmentation can sometimes be found and small abscess formation with 
acute inflammation may be present. (Walton and Torabinejad 1996, Neville et al 2002).  
Most CAPs are asymptomatic with just a little discomfort and CAP is usually discovered in 
routine radiographic examination: radiolucency is present and the affected tooth lacks apical 
lamina dura. The tooth does not respond to electric vitality testing because the pulp is necrotic 
and the percussion sensibility is mild at most. (Walton and Torabinejad 1996, Neville et al 2002).  
The immune-inflammatory process in apical periodontitis is double-faced. On the one hand, it is a 
protective host response to prevent bacterial invasion of the tooth apex and surrounding bone 
tissue, but, on the other the ”protective” mechanism also leads to destruction of the host tissue 
components (Márton and Kiss 2000). The first barrier to prevent bacterial invasion through apical 
foramen is provided by PMNs, which, by active phagocytosis and killing, effectively keep the 
bacterial amount and penetration as low as possible. Monocytes/macrophages also take part in the 
primary phagocytic protective phase and secrete antigens to act as chemotactic stimuli and to 
recruit other cells to participate in the inflammatory reaction (Márton and Kiss 2000). The 
degradation of the mineralised matrix of the alveolar bone surrounding the tooth apex is due to 
the action of osteoclasts (Bohne 1990, Anan et al 1991). In inflammation the delicate balance 
between osteoclasts and osteoblasts is disturbed resulting in bone loss. There are many factors 
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that have a stimulating effect on bone resorption in the apical periodontitis (Fig. 2). These 
stimulating factors include bacterial components, mainly LPS like endotoxin and short-chain 
fatty acids, released to the apical area, as well as host-derived substances. The host-defence 
system stimulates the tissue destructive reactions by releasing arachidonic acid derivates 
(prostaglandins and leukotrienes) during phagocytosis and other cell-mediated inflammatory 
factors, such as cytokines. High levels of immunoglobulins, secreted by plasma cells, are also 
found in periapical lesions (Torres et al 1994, Matsuo et al 1995, Miyauchi et al 1996). Other 
plasma proteins, such as complement components, bradykinin, kallikrein and thrombin and acute-
phase reactants, derived from dilated blood vessels are also present to stimulate bone resorption 
(Lerner 1994, Márton and Kiss 2000). As a response to stimuli, monocyte/macrophage-like cells, 
plasma cells, fibroblasts, epithelial and endothelial cells, PMNs, osteoblasts and osteoclasts in 
periapical periodontitis can produce bone resorptive cytokines IL-1? and IL-1?, TNF-? and IL-6 
(Artese et al 1991, Piattelli et al 1991, Barkhordar et al 1992, Miller et al 1996, Márton and Kiss 
2000). T-cells express IL-2, IL-4, IL-6, IL-10 and interferon-? (IFN-?), and B-cells, fibroblasts 
and monocyte/macrophage-like cells IL-10 (Walker et al 2000). The immune cytokines in CAP 
can accelerate bone resorption (Stashenko 1990). The tissue destructive process is interactive, and 
these cytokines can trigger other cells to express proteolytic enzymes, including MMPs, also 
found to be present in periapical granulation tissue (Barkhordar 1987, Takahashi 1998).(Fig. 2.). 
 
2.2.3 Root canal treatment (RCT) 
 
In order to eliminate the pulpal inflammation to avoid root canal necrosis, prevent or heal 
periapical periodontitis root canal treatment (RCT) has to be performed. The aim of RCT is to 
remove bacteria and their toxins from the root canal by mechanical and chemical cleaning. The 
root canal treatment techniques vary according to the person. The treatment needs to be done 
under aseptic conditions and therefore the tooth is separated from other teeth and the oral cavity 
by a rubber dam and the working area is sterilized. The first step in RCT is to determine the 
working length of the root canal instruments, which is often done by radiographs and/or by 
electrical measuring. The necrotic tissue is removed with special root canal instruments and the 
canal is mechanically widened using rinsing with antiseptic liquids and usually also with liquids, 
like ethylene diamino tetra acetic acid (EDTA), to remove the smear layer from the root canal 
walls. Root filling is done during the same appointment or the next visit. An X-ray is taken to 
check the root filling. The success of the treatment is usually checked within one year of the basic 
treatment. It is considered successful if no clinical symptoms remain and the periapical area in a 
radiological examination seems to be normal without signs of inflammation or resorption. 
(Walton and Torabinejad 1996). The difficulty during RCT is to determine whether the treatment 
has been successful enough to eliminate the bacteria in the root canal environment. If not, it is 
likely that the infection in the apical area persists. Chair-side adjunctive diagnostic tests 
measuring the inflammatory level or mediators of periapical tissue are suggested as future tools in 
endodontics (Metzger 2000).  
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    Figure 2. The bone destructive mechanism in apical periodontitis. 
This figure shows the complicated network of tissue reactions against bacterial products in apical 
periodontitis. (Modified from Márton and Kiss 2000) 
BAG: bacterial antigens, LPS: Lipopolysaccharides, PMN: polymorphonuclear leukocyte, T: T-lymphocyte, B: B-
lymphocyte, Mc: macrophage, Fb: fibroblast, Plc: plasma cell, Ob: osteoblast, Oc: osteoclast, TNF: tumour necrosis 
factor, IL: interleukin, INF: interferon, PGE: prostaglandin, MMP: matrix metalloproteinase. 
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2.3 Odontogenic cysts 
 
“A cyst is described as a pathological cavity, lined usually totally or partly with epithelium, 
containing gas, fluid or semi-fluid and not being created by puss accumulation” (Kramer 1974). 
Cysts are more common in the jawbone than in any other bone. Depending on the epithelial 
origin, jaw cysts are divided into odontogenic and non-odontogenic cysts.  
The epithelial lining of odontogenic cysts is derived from the epithelial remnants of tooth- 
forming organs and these cysts are further divided into developmental and inflammatory cysts. 
Odontogenic developmental cysts are of unknown origin and inflammatory cysts, like their name 
suggests, result from inflammation. Developmental cysts include “gingival cysts” of infants 
(Epstein pearls), odontogenic keratocysts, dentigerous (follicular) cysts, eruption cysts, lateral 
periodontal cysts, gingival cysts of adults and glandular odontogenic cysts (sialo-odontogenic 
cysts). Inflammatory cysts include radicular cysts (apical and lateral, and residual cysts) and 
paradental cysts. Odontogenic cysts comprise 90 % of the jaw cysts. (Kramer et al 1992, Neville 
et al 2002). 
 
2.3.1. Radicular cyst (RC, Periapical cyst, Apical periodontal cyst) 
 
Radicular cysts (RCs) are the most common odontogenic cysts (60-75%). RC originate from the 
epithelial rests of Malassez entrapped within chronic apical periodontitis. When small they are 
usually symptomless but may expand the bone while growing. Eventually, the cyst may perforate 
the cortex but frequently they do not grow to large dimensions. In an X-ray, RC shows a variable 
size of radiolucency with a loss of lamina dura, but the radiographic examination is not a 
diagnostic criteria. 
In RC, non-keratinised stratified squamous epithelium partly or wholly surrounds the chronically 
inflamed granulation tissue capsule. Epithelial hyperplasia is often present and the epithelium 
may demonstrate spongiosis. The cyst lumen is filled with fluid and cellular debris. Sometimes 
the epithelium may include calcifications known as Rushton bodies. Both the cyst lumen and wall 
may present dystrophic calcifications, cholesterol clefts with multinucleated foreign body giant 
cells, red blood cells and hemosiderin pigmentation. The fibrous connective tissue wall of the 
cyst often demonstrates inflammatory infiltrate with lymphocytes, PMN cells, plasma cells, 
histiocytes, and rarely mast cells and eosinophils. Plasma cells often predominate the infiltration. 
The cyst wall occasionally contains hyaline bodies – scattered, circumscribed corrugated, 
condensed collagenous rings containing eosinophilic material - surrounded frequently by 
multinucleated giant cells and lymphocytes. The eosinophilic material may contain various cells 
and it may undergo dystrophic calcification. These bodies can be seen in any intraosseous chronic 
inflammation and they represent inflammatory exudate pools (i.e. extravasated serum) that with 
time undergo fibrosis and occasionally dystrophic calcification. The multinucleated foreign body 
giant cells appear at the site to remove the debris. The cyst wall becomes more fibrotic with 
diminishing vascularity and inflammatory infiltration. (Neville et al 2002). 
 
The RCs tend to expand,”balloon-like”, in all directions equally, and the surrounding bone is 
resorbed, mainly by osteoclast function (Formigli et al 1995). Cyst lining cell cultures have been 
demonstrated to release osteoclast stimulating bone resorbing factors, prostaglandins, mainly 
from cyst capsule fibroblasts, and immunoglobulins are secreted by plasma cells (Formigli et al 
1995, Meghji et al 1996, Takahashi et al 1996). Interleukins and other cytokines are secreted 
from monocyte/macrophage-like cells, epithelial cells and other cells to stimulate bone resorption 
(Bando et al 1993). IL-1?, IL-1?, IL-4, IL-6, IL-10 and IFN-? are detected in RC fluid and 
explant media, IL-1? being characteristics of RCs in comparison to FC and KC (Hoenig et al 
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1991, Formigli et al 1995, Meghji et al 1996, Walker et al 2000). Cytokines are able to trigger 
cells in RC to produce proteolytic enzymes, such as IL-1? which enhances gelatinase-A and -B 
(MMP-2 and MMP-9) production in explant culture (Kubota et al 2000). MMP-1 (collagenase –
1) protein has been found in subepithelial fibroblasts and epithelial cells of RC (Lin et al 1997). 
Collagenases (MMP-1 and MMP-8) and gelatinases (MMP-2 and MMP-9) have been detected in 
cyst fluid and cyst wall extracts (Teronen et al 1995a, b, Kubota et al 2000). Bacterial 
endotoxins, always present in RC, stimulate keratinocyte proliferation, and bacterial products 
activate MMP production (Ding et al 1995, 1996, Meghji et al 1996). These proteolytic enzyme 
cascades are most likely involved in the bone matrix degradation, BM and epithelial cell 
processing during cyst expansion.  
 
2.3.2. Follicular cyst (FC, Dentigerous cyst) 
 
Follicular cysts are next to RCs the most common of odontogenic cysts (10-15%). A FC 
originates from the reduced enamel epithelium derived from the enamel organ. It encloses partly 
or totally the crown of an unerupted tooth and it is attached to the tooth at the cementoenamel 
junction. FCs most frequently surround mandibular third molars, followed by maxillary 
permanent canines, maxillary third molars and mandibular second premolars. FCs are usually 
symptomless, but they may grow to a remarkable size expanding the bone in the involved area. 
Usually they do not show any pain unless secondary inflammation is present. Radiologically, FCs 
usually show unilocular radiolucency attached to an unerupted tooth. (Neville et al 2002). 
The cyst epithelium is usually two to five layers thick. It consists of non-keratinised cells and the 
interface to connective tissue is flat. If inflammation is present, the epithelium may show varying 
amounts of hyperplasia with development of rete ridges. Focal areas of mucous cells (goblet 
cells) may be seen in the epithelial lining, and rarely ciliated columnar or sebaceous cells. The 
connective tissue wall is loosely arranged having sometimes cholesterol clefts and islands of 
odontogenic epithelium present. When inflammation is present, the collagen amount in the cyst 
wall increases with variable infiltration of inflammatory cells. The cyst contains a proteinaceous, 
yellowish fluid frequently with cholesterol crystals. (Neville et al 2002). 
 
The developing stimulus of a FC is unknown and the cyst formation mechanism is still unclear. 
The expansion mechanism of a FC is, anyhow, probably similar to that of a RC but is dependent 
on bone destruction and osmotic pressure (Neville et al 2002). The triggering mechanism in FCs 
for the release of bone resorbing factors from the cyst cells may differ from RCs, because 
inflammation is not necessarily always present. Bone resorption stimulating factors, including 
growth factors and cytokines, are present in a FC wall and epithelium (Meghji et al 1996, Li et al 
1997). These stimuli are able to release MMPs, like gelatinases, from cyst cells (Kubota et al 
2000). Collagenases and gelatinases are found in FC wall extracts (Teronen et al 1995a, b) 
suggesting that these enzymes take part in the FC expansion as well.  
 
2.3.3. Odontogenic keratocyst (KC, Primordial cyst) 
 
Odontogenic keratocyst is the third most common of odontogenic cysts (5-10%). It is thought to 
originate from the cell rests after the dissolution of the dental lamina. Most of the KC cases occur 
in ages 10 to 40 with a slight male predilection and 70-80 % occur in the mandible, most often in 
third molar region and ascending ramus. In maxilla it most often involves the region posterior to 
the first premolar. The expansion mechanism of KCs differs from RCs’ and FCs’ unicentric 
pattern. An odontogenic keratocyst tends to grow in an antero-posterior direction often not 
showing bone expansion. KCs may, however, cause swelling and pain. Radiologically, KCs 
demonstrate a well-defined radiolucent uni- or multilocular area with smooth and often corticated 
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margins. An unerupted tooth is involved in 25-40 % of the cases. The diagnosis of KC is based 
on histopathology, radiologic findings being only suggestive. The recurrence rate of KCs is high 
varying from 3 to 60 %. Recurrence takes place more often in mandibular KC, especially in the 
posterior body and ascending ramus. (Myoung et al 2001, Neville et al 2002). Although the 
majority of KCs appear as solitary lesions, multiple KCs may be present and they are associated 
with nevoid basal cell carcinoma (Gorlin-Goltz) syndrome (Myoung et al 2001, Neville et al 
2002).  
 
The histopathology of a KC often shows a thin friable, folded wall, which is difficult to enucleate 
in one piece. The cyst wall capsule may contain epithelial rests giving the basis to independent 
satellite cysts (daughter cysts) around the main lesion. KC lumen may contain liquid material 
similar to a serum transudate, but often it contains thick cheesy material composed of 
keratinaceous debris having a low soluble protein level. (Neville et al 2002). The epithelial lining 
surrounded by the fibrous cyst capsule is usually composed of six to eight cell layers thick 
squamous epithelium. The uniform thick, often corrugated epithelial surface shows parakeratotic 
epithelial cells but areas of orthokeratosis may be present. The well-defined basal cell layer 
consists of palisaded columnar or cuboidal cells, which are often hyperchromatic. When 
inflammatory changes are present the epithelial lining may lose its keratinization and histological 
characteristics of its basal cell layer and also rete ridge formation may be seen. The epithelium 
easily detaches from the cyst stroma, a phenomenon that may increase the recurrence rate of KCs. 
The orthokeratinized variant (orthokeratinized odontogenic cyst) of the KC is not associated with 
Gorlin-Goltz syndrome and the recurrence rate is much lower, though it has been suggested that 
this orthokeratinized type might have a greater risk for malignancy. The orthokeratinized 
epithelium has a granular layer and the basal layer is poorly organized. Radiographically and 
clinically 2/3 of the orthokeratinized odontogenic cysts show similarities with the follicular cyst; 
most often involving an impacted third lower molar. It is suggested that the orthokeratinized 
odontogenic cyst should be categorized differently from KCs. (Neville et al 2002, Regezi 2002).  
 
The growth and enlargement of KCs has often been regarded as evidence of their neoplastic 
behaviour (Myoung et al 2001, Shear 2002a). Possible inflammation has little effect on the KC 
growth. The latest point based on the multilocular and loculated outlines of the KC is that the 
enlargement of a KC appears in a multicentric growth pattern with proliferation of local groups of 
epithelial cells against the semi-solid cyst contents. The intrinsic growth potential and infolding 
of the epithelium into the cyst wall during the KCs multiphase growing indicate active epithelial 
proliferation and support the suggestion that KC may more likely present a benign neoplasm than 
a cyst (Shear 2002a, c). The finding that KC epithelial cells overexpress p53, a protein usually 
overexpressed in malignant lesions but not in normal cells, further strengthens the notion of KCs’ 
potential neoplastic nature (Piattelli et al 2001). A mutation in the p53 gene may be a reason for 
the increased cell proliferation. The p53+ basal cells are found more often in KCs with epithelial 
dysplasia and the p53+ epithelium is usually parakeratotic (Piattelli et al 2001). The proliferating 
cell nuclear antigen (PCNA), indicating active proliferation in p53+ cells, is also found more 
often in KCs than other odontogenic cysts (Li et al 1994, Piattelli et al 2001, Shear 2002b). It has 
been shown that the KC epithelium has higher mitotic activity than FC or RC epithelia, and the 
mitotic activity is often found in basal or suprabasal cells (Matthews et al 1988, Li et al 1994). 
The dissolution of bone matrix by the cyst wall is mediated by osteoclasts, evidently in concert 
with the biologically active proteases, including MMPs (Neville et al 2002). Different cytokines 
and other cell mediators, produced in a KC as well, can stimulate the protease production or 
activation by KC cells. KC epithelial cells can further express TGF-?, IL-1?, IL-6 and proMMP-
9 (Meghji et al 1992, 1996, Li et al 1997, Kubota et al 2000). IL-1 is able to enhance MT1-MMP 
expression in KC fibroblasts and increases both proMMP-2 and proMMP-9 activation (Kubota et 
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al 2000, 2002). Active interstitial collagenases (MMP-1 and MMP-8) and gelatinases (MMP-2 
and MMP-9) have been found in the cyst extracts and fluids (Ylipaavalniemi 1978, Teronen et al 
1995a, b, Sorsa et al 1988, Kubota et al 2000). 
The reasons for KCs’ special characteristics, epithelial detachment and growth potential, are not 
yet completely clarified and require further studies. 
 
 
2.4 Plasma cells 
 
Plasma cells accumulate in chronic inflammation and by tradition their role is to act in the 
humoral immune response by secreting antibodies. They derive from B lymphocytes and their 
differentiation requires multiple stimuli. The primary stimulus is antigen interaction with surface 
immunoglobulins (IgM and IgG) of B lymphocyte. The activated B lymphocyte ”presents” the 
antigen to T-helper lymphocytes that in turn secrete distinct growth and differentiation factors. 
These molecules, particularly IL-4 and IL-5, secreted by T-helper cells, induce B cell 
differentiation. The final differentiation requires an additional B cell differentiation factor, IL-6 
secreted by many lymphoid and nonlymphoid cells, to be present (Nisengard and Newman 1994). 
Also other cytokines, IL-3 and IL-10, with T cell induction may activate the B cell differentiation 
into plasma cells (Merville et al 1995, Rousset et al 1995). 
 
The main function of plasma cells is to secrete immunoglobulins, antibodies taking part in the 
host defence system, by binding to antigens. Antibody secretion is the basis of humoral 
immunity. Antibodies are active against bacteria, viruses and tumours, and they are able to 
neutralize a number of microbial products, particularly toxins, which can be harmful to the host 
tissues. Immunoglobulins are glycoproteins containing a basic monomeric structure consisting of 
two heavy and two light chains. Based on differences in the H chain region, immunoglobulins are 
divided to five main groups: IgM, IgG, IgA, IgD and IgE, and based on L chain dissimilarities to 
? and ? subgroups. Plasma cells produce immunoglobulins and antibodies against foreign 
antigens, but they are also known to produce and secrete antibodies against self antigens leading 
to autoimmune diseases (Andrew et al 1991), and also certain cytokines (IL-10, TGF-?1, TNF-?) 
(Matthes et al 1995, DiGirolamo et al 1997). Plasma cells, specially myeloma cells, and B 
lymphocytes also secrete certain matrix metalloproteinases (MMP-2, MMP-3 and MMP-9) and 
their inhibitors (TIMP-1) (Stetler-Stevenson et al 1997, DiGirolamo et al 1998). 
 
2.4.1 Multiple myeloma (MM) and plasmacytoma (PLC) 
 
Multiple myeloma is the most common plasma cell malignancy. It generally occurs as a 
disseminated lesion involving many bones (multiple myeloma) or seldom as a solitary bone/soft 
tissue lesion (solitary myeloma or plasmacytoma/extramedullary plasmacytoma). 
Plasmacytoma may lead to multiple myeloma. MM is a progressive and fatal malignancy of 
plasma cells. It may involve IgA, IgD or IgE but most frequently involving IgG producing 
monoclonal plasma cells. In MM abnormally high levels of the immunoglobulin or its 
polypeptide chains are secreted into the serum and urine. Most often MM appears in patients 
between 50 and 70 years affecting men more often than women. The skull, vertebrae, sternum, 
ribs and pelvic bones are commonly affected though lesions in jaws are not uncommon (30% of 
the cases). Jaw lesions appear more commonly in the posterior region of the mandible. The bone 
lesions present unbalanced bone remodelling: excessive resorption with low bone formation. 
(Neville et al 2002). 
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The most characteristic of the clinical symptoms of MM is bone pain and some patients may 
present pathologic fractures caused by bone destruction. Patients may suffer from anaemia and 
fever may be present as a result of neutropenia. Metastatic calcifications may occur in soft tissues 
due to hypercalcemia caused by osteolysis. The excess of produced light chains, unattached to 
heavy chains are excreted to the urine and often precipitate in renal tubules, and may cause renal 
failure. This light chain protein found in the urine is called Bence-Jones protein. Amyloidosis 
may appear even as an initial manifestation of the disease. This deposition of extracellular 
proteinaceous substance, amyloid, often affects the eyelid region, and when present in the tongue 
may lead to macroglossia. Radiographically MM appears as sharply demarcated radiolucencies or 
ragged radiolucent areas often well evidenced in skull radiographs. Histologically these lesions 
show dense cellularity with little or no supporting stroma. The lesions consist of variably 
differentiated, plasmacytoid cells invading and replacing the normal host tissue. Occasionally 
homogenous, relatively acellular amyloid material may be present among neoplastic cells. 
(Neville et al 2002). The criteria to diagnose MM are seen in the Table 1. 
 
Table 1.  Diagnostic criteria for plasma cell myeloma 
  (Modified from WHO criteria; edited by Jaffe et al 2001) 
 
The myeloma diagnosis requires a minimum of one major or three minor criteria which must 
include (1) and (2). These criteria must be manifest in a symptomatic patient with progressive 
disease. 
 
Major criteria: 1.  Marrow plasmacytosis (>30%) 
   2.  Plasmacytoma on biopsy 
   3.  M-component: Serum IgG > 3.5g/dl, IgA >2g/dl  
                 Urine >1g/24hr of Bence-Jones (BJ) protein 
  
Minor criteria: 1.  Marrow plasmacytosis (10-30%) 
   2.  M-component: present but less than above 
   3.  Lytic bone lesions 
   4.  Reduced normal immunoglobulins (<50% normal): 
                   IgG <600mg/dl, IgA <100mg/dl, IgM <50mg/dl 
     
 
              
In addition to immunoglobulin secretion, the plasma cells in MM excrete many different 
cytokines and MMPs. IL-6 has been widely studied and its expression by malignant plasma cells 
is related to MM invasiveness (Pattengale 1997, Sati et al 1998). IL-6, not expressed in normal 
plasma cells, is essential for the growth of MM, by inducing the differentiation of plasmablasts 
into mature malignant plasma cells (Lauta 2001), and for the survival of myeloma cells by 
preventing spontaneous apoptosis (Pattengale 1997). Myeloma cells, in addition to secreting IL-
6, also stimulate stromal and bone marrow cells to release large amounts of IL-6 via an IL-1 
dependent pathway (Carter et al 1990). Cytokines are able to provoke IL-6 production in bone 
marrow-derived stromal cells and cytokines provoke MMP production and secretion by many 
cells, though IL-6 has not been found to interfere with MMP production in MM lesions (Carter et 
al 1990, Barille et al 1997, Vacca et al 1999). The MM plasma cells interfere with the invasive 
potential of MMs also by secreting fibroblasts growth factor (FGF-2), a potent angiogenic factor, 
to increase angiogenesis (Vacca et al 1999). MM cells can produce gelatinases (MMP-2 and 
MMP-9), and upregulate collagenase-1 (MMP-1) expression and induce MMP-2 activation in 
bone marrow stromal cells of MM patients (Barille et al 1997, Vacca et al 1999, Ria et al 2002). 
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MMPs (MMP-1, MMP-2, MMP-9) expression of MM cells is known to increase during the 
active phase of the disease (Barrille et al 1997, Vacca et al 1999). The ECM proteins fibronectin 
(FN) and vitronectin (VN) are known to enhance MM plasma cell proliferation and gelatinase 
(MMP-2 and MMP-9) release from MM cells via ?V?3 integrin pathway (Ria et al 2002). 
 
 
2.5 Laminin-5 (Ln-5) 
 
Laminins are a family of non-collagenous BM proteins that appear in several isoforms each 
presenting a unique combination of ?, ? and ? chain linked together with disulfide bonds. In 
addition to acting as structural components, laminins are involved in the cell differentiation, 
adhesion and migration. (Lohi 2001). 
Ln-5, previously called kalinin, nicein or epiligrin, functions as an anchoring filament component 
between epithelial cells and the BM. Keratinocytes synthesize Ln-5 (Amano et al 2001) and it 
consists of ?3: ?3: ?2 subunits of which the ?2 chain is unique for Ln-5 (Kallunki et al 1992). Ln-
5 has an ambiguous role both in promoting cell adhesion and migration and its overexpression in 
tissues is closely related to malignancy (Soini et al 1996, Lohi 2001, Patel et al 2002). The cell 
adhesive function of intact Ln-5 is mediated through ?3?1 and ?6?4 integrins being connected to 
type VII collagen in the BM (Rousselle et al 1997). The ?2 chain does not contribute to the 
adhesive quality of Ln-5, but plays a crucial role in the regulation of cell migration (Salo et al 
1999). The specific cleavage of a ?2 chain to a 80 kDa form has been reported to cause epithelial 
cell migration and is connected to cell invasiveness (Giannelli et al 1997, Skyldberg et al 1999, 
Gilles et al 2001). MMP-2, -3, -13, -14, -20 and MT1-MMP are among the MMPs able to cleave 
Ln-5 at a special site in order to promote epithelial cell motility (Giannelli et al 1997, 1999, 
Koshikawa et al 2000, Gilles et al 2001, Pirilä et al 2001b, 2003). These findings suggest that a 
fragmented laminin ?2 chain has a specific role in the regulation of the epithelial cell migration. 
 
 
2.6 Matrix metalloproteinases (MMPs) 
 
Matrix metalloproteinases form a structurally related group of at least 25 (22 human homologues) 
Ca2+- and Zn2+-dependent endopeptidases collectively capable of degrading practically all ECM 
and BM components. In addition, MMPs can modulate many other substrates including ILs and 
other cytokines, serine proteinase inhibitors (serpins), growth factors and chemokines (Uitto et al 
2003). MMPs are divided into six subgroups: collagenases, gelatinases, membrane-type MMPs 
(MT-MMPs), stromelysins, matrilysins and other MMPs (Fig. 3 and Table 2). They have a role in 
many normal physiological events, like ovulation, embryo implantation, organ development, 
angiogenesis, wound healing and bone remodelling. Normal embryonic development and tissue 
remodelling needs a controlled balance between ECM synthesis and degradation, as well as a 
balance between MMPs and their natural inhibitors TIMPs. Overproduction of MMPs occurs in 
many tissue destructive pathological conditions and MMPs are known to influence many chronic 
tissue destructive inflammatory and autoimmune diseases, like rheumatoid arthritis, 
osteoarthritis, periodontitis, blistering disorders of the skin, lung diseases, eye diseases and 
chronic ulcerations. They also affect tumour growth, invasion and metastasis. In the 
inflammatory process, MMPs, being upregulated by cytokines and other proinflammatory 
mediators, are mainly responsible for the ECM and BM degradation. (Kähäri and Saarialho-Kere 
1999, Johansson et al 2000). MMPs are active in physiological and pathological bone 
remodelling being expressed by osteoblasts and osteoclasts (Rifas et al 1989, Meikle et al 1992, 
Vaes et al 1992, Reponen et al 1994, Wucherpfennig et al 1994). 
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In addition to tissue remodelling, MMPs participate in many other cellular functions (Vu and 
Werb 2000). They adapt cellular behaviour, for example, by inducing cell migration in normal 
growth and tissue remodelling, such as wound healing, angiogenesis, as well as in tumour 
invasion and metastasis (Curran and Murray 2000, Johansson et al 2000, Vu and Werb 2000, 
Vihinen and Kähäri 2002). Molecules affecting cellular functions can be modified by MMPs; the 
precursor of IL-1? can be activated by MMP-2, MMP-3 and MMP-9, although excess or 
prolonged incubation with MMPs can also result in IL-1? inactivation (Ito et al 1996, Schönbeck 
et al 1998). 
Extracellular matrices themselves adjust to the cellular functions, like growth, cell shape changes, 
migration and differentiation, for example, by controlling cellular adhesion. An ECM influences 
cell behaviour by maintaining signal molecules, such as growth-factors and growth-factor binding 
proteins, and acting as a ligand for cellular receptors, including integrins, that can transduce 
signals to the cell interior. MMPs may cleave the ECM and release bioactive cell surface 
molecules or regulate the growth-factor availability by cleaving the ECM proteins that can bind 
to them (Uitto et al 2003). Various MMPs can degrade decorin, a collagen-associated small 
protein that binds to TGF-?, and may as a ”secondary effect” release TGF-? to carry out its 
biological functions. On the other hand, the release of TGF-? may have a negative feedback on 
MMP production. (Sternlicht and Werb 2001, Uitto et al 2003).  
MMPs modulate the activity of other proteinases by activating latent enzymes or inactivating 
their inhibitors. MMP-3 can cleave the urokinase type plasminogen activator and MMP-1 and 
MMP-8 are able to cleave the ?1-proteinase inhibitor and ?1-antichymotrypsin (Michaelis et al 
1990, Vu and Werb 2000). MMPs are also able to activate each other in a complicated cascade 
network. MMP-2 and MT1-MMP, for example, are able to activate latent MMP-13, and MT1-
MMP activates MMP-8, as well as the active form of MMP-2 together with MMP-13 activate 
MMP-9 (Knäuper et al 1996a, Cowell et al 1998, Saarialho-Kere 2000, Holopainen et al 2003). 
MMPs’ behaviour in tissues is multivariate and many questions are still unanswered (Uitto et al 
2003). MMPs share significant structural similarities; all of them contain the N-terminal signal 
sequence (”pre”domain) followed by the ”pro”domain that maintains enzyme latency usually 
until removed, and the zinc-binding catalytic domain. With three exceptions (MMP-7, MMP-23 
and MMP-26) the hemopexin/vitronectin domain is connected to the catalytic domain. The 
hemopexin domain participates in the catalytic activities and it can bind to TIMP and certain 
substrates (Sternlicht and Werb 2001). MT-MMPs contain a transmembrane domain and a short 
cytoplasmic C-terminal tail (Fig. 3).  
 
 
2.6.1 Collagenases  ( MMP-1, MMP-8, MMP-13) 
 
The human interstitial collagenase subfamily contains three members: MMP-1 (fibroblast type 
collagenase, collagenase-1), MMP-8 (neutrophil collagenase, collagenase-2) and MMP-13 
(collagenase-3). In addition to these human collagenases, a collagenase, MMP-18, has been found 
and cloned only from Xenopus laevis (Stolow et al 1996). The mammalian analogous has not yet 
been found.  
Collagenases cleave the native fibrillar collagen types I-III to generate ¾- and ¼-fragments. The 
cleavage takes place in a specific site between the glysine-isoleusine (Gly-Ile) of the ?1 chain 
and the glysine-leusine (Gly-Leu) residues of the ?2 chain forming triple helical fragments that in 
body temperature denature into randomly coiled gelatin, being further degraded by other 
gelatinolytic MMPs and proteinases (Birkedal-Hansen et al 1993, Sternlicht and Werb 2001). 
The collagenases differ in their substrate specificities and functional roles. MMP-1 preferably  
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Figure 3.     MMP structure (Modified from Sternlich and Werb 2001) 
Pre: Pre domain, Pro: propeptide with ZN-binding thiol group (SH), Fu: furin site, ZN: Zn-
binding site, F: fibronectin type II insert, H: Hinge region, TM: transmembrane domain, C: 
cytoplasmic tail, C/P:cysteine/proline, IL-1R: interleukin-1 receptor. 
1)  Minimal Domain MMPs   
MMP-7: matrilysin, MMP-26:endometase 
2)  Simple Hemopexin Domain-Containing MMPs 
MMP-1: collagenase-1, MMP-8: collagenase-2, MMP-13: collagenase-3, MMP-18:          
collagenase-4, MMP-3: stromelysin-1, MMP10: stromelysin-2, MMP-27, MMP-12: 
metalloelastase, MMP-19:RASI-1, MMP-20: enamelysin, MMP-22: CMMP 
3) Gelatin-binding MMPs 
MMP-2: gelatinase-A, MMP-9: gelatinase-B 
4) Furin activated Secreted MMPs 
MMP-11: stromelysin -3, MMP-28: epilysin 
5)  Transmembrane MMPs 
MMP-14: MT1-MMP, MMP-15: MT2-MMP, MMP-16: MT3-MMP, MMP-24: MT5-MMP 
6)  GPI-linked MMPs 
 (glycophosphatidyl 1 inositol-anchoring domain) 
MMP-17: MT4-MMP, MMP-25: MT6-MMP 
7) Vitronectin-like MMPs      MMP-21: XMMP 
8) Cysteine/Proline-rich IL-1 Receptor-like Domain MMPs      MMP-23 
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degrades collagen III, MMP-8 prefers type I collagen (Birkedal-Hansen et al 1993), and MMP-13 
collagen II (Knäuper et al 1996a) (Table 2).  
 
Human MMP-1 was first cloned and sequenced from skin fibroblasts (Goldberg et al 1986). 
Since then it has been found to be produced by keratinocytes, endothelial cells, monocytes and 
macrophages, chondrocytes, osteoblasts and various tumour cells (Meikle et al 1992, Birkedal-
Hansen et al 1993, Giambernardi et al 1998). MMP-1 is produced on demand by transcriptional 
initiation and the delay after the trigger mechanism can be up to 12 hours (Birkedal-Hansen et al 
1993). It is produced as glycosylated proenzymes 52 kDa and 57 kDa in size, and upon activation 
(i.e. propeptide cleavage or removal) converted to the active size of 42 kDa and 47 kDa 
respectively. MMP-1 cleaves several ECM components but is ineffective against most BM 
components. It has been connected to many physiological phenomena, like embryonic 
development and the migration of keratinocytes during wound healing, as well as to the growth of 
malignant tumours (Saarialho-Kere et al 1992, 1995, Vaalamo et al 1997, Giambernardi et al 
1998, Vu and Werb 2000). 
 
MMP-8 is synthesized and stored in PMN cells during their maturation in bone marrow and 
released upon PMN degranulation induced by various extracellular stimuli, like cytokines or 
bacterial contact (Ding et al 1995, 1996, 1997). In addition inducible de novo MMP-8 expression 
has been found to be expressed by chondrocytes, fibroblast-like cells, monocytes, epithelial cells 
and keratinocytes, as well as melanoma cells and oral cancer cells (Hanemaaijer et al 1997, 
Giambernardi et al 1998, Bachmeier et al 2000, Tervahartiala et al 2000, Prikk et al 2001, 2002, 
Moilanen et al 2002). MMP-8 is secreted either as a 55 kDa unglycosylated form or a 75 kDa 
glycosylated form and after activation its molecular size usually decreases by 10-20 kDa (Hasty 
et al 1990, Ding et al 1995, Hanemaaijer et al 1997, Moilanen et al 2003). The main substrates 
for MMP-8 are fibrillar collagens (Birkedal-Hansen et al 1993). MMP-8 is catalytically more 
effective in cleaving substrates (except collagen III) than MMP-1. Increased MMP-8 levels are 
detected in many inflammatory diseases like rheumatoid arthritis, chronic lung inflammations and 
periodontitis (Konttinen et al 1991, Sorsa et al 1994, 1999, Ingman et al 1996, Uitto et al 1998, 
Tervahartiala et al 2000, Mäntylä et al 2000, 2003, Marchenko et al 2001a, b, Prikk et al 2001, 
2002, Lanone et al 2002). 
 
MMP-13 has the widest substrate selection among the interstitial collagenases and, in addition to 
collagens, it is able to cleave various BM components. MMP-13 cleaves type II collagen more 
efficiently than type I and III and among interstitial collagenases, it is most effective in cleaving 
gelatin (Mitchell et al 1996, Lindy et al 1997). It is secreted as a 60 kDa glycoprotein and is 
converted to a 48 kDa form after activation. MMP-13 can be activated by other MMPs including 
MMP-2, MMP-3, MMP-10, MT1-MMP, MT2-MMP and serine proteases human trypsin-2 and 
plasmin (Knäuper et al 1996a, b, D’Ortho et al 1997). MMP-13 was first cloned from human 
breast cancer, indicating a role in malignancy (Freije et al 1994). The physiologic expression of 
MMP-13 seems to be limited only to developing bone (Ståhle-Bäckdahl et al 1997) and wound 
healing (Ravanti et al 1999, Pirilä et al 2001b), but it is widely expressed in pathological 
conditions characterized by excessive ECM degradation including rheumatoid arthritis, 
osteoarthritis, periodontitis and chronic ulcerations (Lindy et al 1997, Vaalamo et al 1997, Uitto 
et al 1998, Johansson et al 2000, Tervahartiala et al 2000, Kiili et al 2002). MMP-13 is further 
expressed in skin and mucosal squamous cell carcinoma (SCC) cells, hypertrophic chondrocytes, 
osteoblasts, and many carcinoma and melanoma cells (Mitchell et al 1996, Johansson et al 1997a, 
b, Giambernardi et al 1998, Uria et al 1998, Bachmeier et al 2000, Hofmann et al 2000, Thomas 
et al 2000). Due to the relative wide substrate specificity, MMP-13 is regarded to be an all-round 
tool for malignant cells in growth and invasion (Kähäri and Saarialho-Kere 1999). 
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2.6.2 Gelatinases (type IV-collagenases, MMP-2, MMP-9) 
 
The gelatinase subgroup contains two enzymes: gelatinase-A (MMP-2) and gelatinase-B (MMP-
9). The substrate specificity and primary structure of gelatinases are rather similar (Fig. 3, Table 
2). Within their catalytic domain, gelatinases have three head-to-tail cysteine-rich repeats that are 
required to bind and cleave especially the denatured collagen and elastin. These inserts resemble 
the collagen binding type II repeats of fibronectin. 
 
 MMP-2 was first purified from a murine malignant melanoma tumour and found to be a potent 
BM type IV collagen degrading enzyme (Salo et al 1983). It is expressed in many different cell 
types including keratinocytes, fibroblasts, chondrocytes, monocytes, osteoblasts, endothelial 
cells, T-lymphocytes and malignant plasma cells, leukaemia, carcinoma and melanoma cells 
(Stetler-Stevenson 1990, Barille et al 1997, Giambernardi et al 1998, Sutinen 1998). PMNs do 
not express or contain MMP-2. The latent MMP-2 is secreted in a 72 kDa form and upon 
activation is converted to a 59-62 kDa form. Collagens (I, II, IV, V, VII, X, XI), gelatins and BM 
components are cleaved by MMP-2 (Aimes and Quiqley 1995, Konttinen et al 1998, Sternlicht 
and Werb 2001). MMP-2 is involved in many processes that require ECM remodelling and its 
overexpression is closely connected to cell migration and to the invasive and metastatic potential 
of malignant tumours (Stetler-Stevenson 1990, Autio-Harmainen et al 1992, Tryggvason et al 
1993, Soini et al 1994, Mäkelä et al 1999, Pirilä et al 2001b, Vihinen and Kähäri 2002).  
 
MMP-9 was originally identified from human macrophages (Vartio et al 1982) but is produced 
by PMNs, keratinocytes, T-lymphocytes, monocytes, plasma cells and many transformed and 
malignant cells (Wucherpfennig et al 1994, DiGirolamo et al 1998, Giambernardi et al 1998). 
The substrate specificity of MMP-9 is similar to MMP-2, though it does not degrade type I-III 
collagens as widely as MMP-2. MMP-9 plays an essential role in the resorption of collagen 
during bone remodelling and development (Meikle et al 1992, Vaes et al 1992, Wucherpfennig et 
al 1994) and its overexpression is also connected to the inflammatory reaction in lung and 
periodontal diseases (Westerlund et al 1996, Mautino et al 1997, Hoshino et al 1998, Atkinson 
and Senior 2003). Tumour cells and their metastatic potential, as well as cell invasion, are also 
linked to MMP-9 (Stetler-Stevenson 1990, Giambernardi et al 1998, Hofmann et al 2000, 
Thomas et al 2001, Vihinen and Kähäri 2002). The MMP-9 level is elevated in chronic wounds 
(Mirastschijski et al 2002, Peled et al 2002).   
 
 
2.7 Regulation of MMPs 
 
2.7.1 Transcriptional regulation of MMP expression 
 
MMPs are expressed at a low rate in normal tissues but on demand their production and 
activation can be promptly induced. MMP-8 and MMP-9 are stored in PMN subcellular granules 
for a rapid release called selective degranulation, and MMP-7 storage in secretory epithelial cells 
in exocrine glands is an exception to this inductive de novo production (Johansson et al 2000). 
MMP expression is regulated at the transcriptional level by many growth factors and cytokines, 
oncogenes, hormones, ECM components and various cell-to-cell interactions. The stimulation of 
MMP expression by many growth factors and cytokines usually involves the activation protein-1 
(AP-1) pathway. The extracellular stimulus activates the AP-1 transcription factor complexes to 
bind into the AP-1-binding site in the MMP gene stimulating MMP expression. AP-1 
transcription factors regulate gene expression not only involved in development, differentiation 
 27
and proliferation, but also in stress reactions, inflammation and tumour progression (Angel and 
Karin 1991). The AP-1 binding site is often accompanied by another sequence called polyoma 
virus enhancer A binding protein 3 (PEA-3). The PEA binding site is activated in most MMP 
genes by oncogene-, growth factor- and phorphol ester-responsible elements (Gutman and 
Wasylyk 1990). Simultaneous activation of MMP-genes via the AP-1 and PEA sites is involved 
in the MMP regulation during tumour progression (Wernert et al 1992). The TGF-? affects the 
transcription through a special mechanism that involves a TGF-? inhibitory element (TIE) found 
in many MMP genes (Kerr et al 1990). 
 
The influence of certain extracellular stimuli is variable depending on the stimulus, cell type and 
MMP gene in question. Many cytokines, like IL-1 and TNF-?, upregulate the inducible MMP 
production (MMP-1, MMP-3, MMP-7, MMP-8, MMP-9, MMP-13, and MMP-14) in many cell 
lines, while TGF-?, glucocorticoids, IFN-? and retinoid acid have mainly suppressive effect. 
TGF-? reduces MMP-9 production in fibroblasts (Overall et al 1991) and also blocks the 
induction of MMP-1 and MMP-3 while it induces the production of MMP-2, MMP-9 and MMP-
13 in keratinocytes and MMP-7 in glioma cells (Salo et al 1991, Nakano et al 1993, Johansson et 
al 1997b). IL-1?, TGF-? and the epidermal growth factor (EGF) induce high-level MMP-3 
expression in synovial fibroblasts, but MMP-10 expression is induced in keratinocytes (Birkedal-
Hansen et al 1993). Some cell-to-cell adherence proteins, ECM proteins, bacterial cells and 
products and hormones may also stimulate the MMP production and secretion (Saarialho-Kere et 
al 1992, 1993, Ding et al 1996, 1997). The production of MMP-2 and MMP-14 is only 
moderately influenced by transcriptional regulation (Birkedal-Hansen et al 1993, Kähäri and 
Saarialho-Kere 1999). Overall, it is clear that the transcriptional regulation of MMP production is 
a very complicated phenomenon including the regulation of the production and degradation of 
transcription factors and the regulation of their trans-activating activities and via these processes 
modulate MMP production in cells. 
 
2.7.2 MMP activation  
 
MMPs are secreted in biologically latent proenzyme or zymogen forms that require activation to 
be catalytically competent in the extracellular milieu or at cell surfaces. The activation 
mechanisms in vivo are not yet completely understood and at least three different pathways have 
been described.   
 
Cleavage by furin-like serine proteases can activate certain MMPs, like MMP-11, MMP-28 and 
MT-MMPs, intracellularly in the Golgi apparatus before secretion as an active enzymes (Pei and 
Weiss 1995). The proMMPs latency is maintained by a ”cysteine switch”, the interaction between 
cysteine residue and zinc ion. During activation the opening of the Cys-Zn2+ bond allows Zn2+ to 
react with H2O to maintain the stabilized open form of MMP, after which it still needs to pass 
through several structural changes to become fully active. Several chemical agents, like 
organomercurials, metal ions (Au2+, Hg2+), thiol reagents, detergents and oxidants can activate or 
induce the ”cysteine switch” reaction by interacting directly with the Cys-residue. Certain 
proteinases, such as plasmin, chymotrypsin, cathepsin, trypsins, neutrophil elastase, kallikrein 
and mast cell tryptase, and also other MMPs, as well as bacterial and fungal proteases, can also 
induce the activation pathway by a series of successive and/or single cleavages (Sorsa et al 1992, 
1997, Birkedal-Hansen et al 1993, Knäuper et al 1996b, Liu et al 2002, Moilanen et al 2003). 
MMP-9 has recently been detected to be active in binding to a substrate even in its proform, but 
still the activation needs the disengagement of the propeptide from the enzyme. This activation 
model is thought to take place via binding to a ligand or substrate (Bannikov et al 2002). In this 
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regard in vivo fully activated MMP-9 species with molecular size of 92 kDa have been detected 
in periodontitis-affected gingival crevicular fluid (GCF) (Westerlund et al 1996). 
 
MMP-2, MMP-8 and MMP-13 can be activated by MT-MMPs (Deryugina et al 2001, Knäuper et 
al 1996b, Holopainen et al 2003). Activation of MMP-2 by MT1-MMP involves TIMPs. TIMP-2 
binds to MT1-MMP and to proMMP-2 and another free TIMP-2 molecule is needed to mediate 
the cleavage and activation of bound MMP-2 by MT1-MMP (Deryugina et al 2001). Human 
MT2-MMP and MT4-MMP are unable to activate MMP-2 (Sternlicht and Werb 2001). The cell 
surface activation of MMP-13 by MT1-MMP can be direct or enhanced with proMMP-2 
(Knäuper et al 1996b). 
The activation of MMPs by each other is an intricate network (Fig. 4). MMP-3 is able to activate 
MMP-1, proMMP-2, MMP-8 and MMP-9. Active MMP-2 and MMP-13 can in collaboration 
activate proMMP-9, MMP-13 can be activated by MMP-2, MMP-3 and MMP-10.  MT-MMPs 
can activate MMP-2, MMP-8 and  MMP-13 (Knäuper et al 1996b, 1997, D’Ortho et al 1997, 
Cowell et al 1998, Curran and Murray 2000, Deryugina et al 2001, Holopainen et al 2003). 
MMP-7 can activate proMMP-8 and –9 (Balbin et al 1998, vonBredow et al 1998). However, 
since almost all human MMPs are expressed and secreted into an extracellular milieu in a latent 
proform, another type of protease is seemingly required to initially activate the first latent 
proMMP in the MMP activation network (Kähäri and Saarialho-Kere 1999, Uitto et al 2003). 
One potent candidate for such action is the tumour-associated trypsin-2 (TAT-2) (Sorsa et al 
1997, Nyberg et al 2002, Moilanen et al 2003). 
 
 
Figure 4. MMPs activation network together with the initial activator TAT-2 
                (Modified from Ala-Aho 2002). 
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2.7.3 MMP inhibition 
  
There are different mechanisms to inhibit or down-regulate MMPs. Inhibition may take place by 
interaction with an active Zn2+-site or by cleaving the active enzyme or binding it to a non-active 
complex form. To influence the MMP levels it is also possible to down-regulate MMPs at the 
transcriptional level (Birkedal-Hansen et al 1993). 
 
Tissue inhibitors of metalloproteinases (TIMPs) represent a multigene family with four members 
(Stetler-Stevenson et al 1989, Birkedal-Hansen et al 1993, Apte et al 1994, Leco et al 1994). 
They inhibit most MMP family members reversibly and the TIMPs are the major endogenous 
extracellular MMP regulators. Inhibition by TIMPs takes place via developing a MMP-TIMP 
complex or by inhibiting the activation of proMMPs (Goldberg et al 1989, Sorsa et al 1992, 
Birkedal-Hansen et al 1993). Different cells express TIMPs and they have been identified not 
only in tissues, but also in body fluids including gingival crevicular fluid (GCF) (Birkedal-
Hansen et al 1993, Leco et al 1994, Sorsa et al 1994, Ingman et al 1996, Lin et al 2001).  TIMP 
inhibition of MMPs is considered to exert a role in healing wounds, bone remodelling and tumour 
invasion (Edwards et al 1996, Vaalamo et al 1996, Sutinen et al 1998). Nonetheless, TIMP-3 is 
an exception, since it is mostly bound to ECM (Birkedal-Hansen et al 1993, Leco et al 1994). 
TIMP-2 has a special role in the regulation of MMP-2 activation by MT1-MMP on the cell 
membranes (Deryugina et al 2001). TIMPs also have growth-promoting properties (Hayakawa et 
al 1992, 1994). The delicate balance between TIMPs and MMPs evidently plays a important role 
in most normal tissue remodelling phenomena and in many tissue destructive inflammatory and 
malignant pathological conditions (Khokha et al 1989, Poulsom et al 1992, Ingman et al 1996, 
Stetler-Stevenson et al 1997, Sutinen et al 1998, Soini et al 2001). 
 
Serum ?2-macroglobulin (?2M) is a natural MMP inactivator and it entraps and bonds to the 
MMP after the enzyme has revealed the ?2M-bait region. The trapping mechanism is irreversible 
but does not block the active site totally, so the enzyme is partly active for low molecular weight 
substrates. The ?2M-proteinase combination is cleared from the circulation in the liver through 
uptake by special receptors (Birkedal-Hansen et al 1993).  
 
Chelating agents, such as EDTA and 1,10-phenenthroline, bind to Zn2+ at the active site 
inhibiting MMPs non-selectively but are regarded as therapeutically useless (Birkedal-Hansen et 
al 1993). Bisphosphonates are a group of MMP inhibiting and down-regulating pharmacologic 
compounds which seemingly also act as chelating agents (Teronen et al 1997, 1999, Heikkilä et 
al 2002, 2003, Vihinen and Kähäri 2002).  
 
Doxycycline and chemically modified non-antimicrobial tetracyclines (CMTs) inhibit MMPs by 
chelating and down-regulating their mRNA and protein expressions (Sorsa et al 1994, Golub et al 
1995, Hanemaaijer et al 1997, Pirilä et al 2001ba). CMTs inhibit especially the pathologically 
elevated MMP-dependent periodontal soft tissue breakdown and bone destruction in vivo and in 
vitro (Golub et al 1995, 1998) and tumour cell proliferation and invasion (Lukkonen et al 2000, 
Gu et al 2001, Lokeshwar et al 2002). CMTs have also been tested in animals and shown to 
inhibit caries progression in tooth and tumour growth and metastasis as well as prevent 
inflammatory bone resorption (Golub et al 1998, Sulkala et al 2001, Bezerra et al 2002, 
Lokeshwar et al 2002). When combined with bisphosphonates, CMTs synergistically inhibit 
bacterial-produced periodontal soft and hard tissue breakdown (Llavaneras et al 1999, 2001). 
Peptidomimetic matrix metalloproteinase inhibitors (MMPI) mimic the structure of MMP 
substrates, as well as function as competitive inhibitors (Vihinen and Kähäri 2002). Batimastat is 
the first synthetic clinically tested MMP inhibitor interacting with Zn2+ in their catalytic site. 
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Animal model studies have shown the inhibition of tumour growth, metastasis, and of 
angiogenesis (Curran and Murray 2000). Marimastat is the second-generation synthetic wide 
spectrum MMP inhibitor that has been clinically evaluated as an anticancer agent (Curran and 
Murray 2000, Vihinen and Kähäri 2002). CTTHWGFTLC-peptide is a selective gelatinase 
(MMP-2 and MMP-9) inhibitor (Koivunen et al 1999, Pirilä et al 2001b, 2003) 
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Table 2. Matrix metalloproteinases  (Modified from Sternlicht and Werb 2001) 
 
MMP    Enzyme                         Substrates_______________________________________                                        
Collagenases 
MMP-1 collagenase-1  aggrecan, collagens I-III,VII,VIII,X,XI, entactin, FN,gelatin, IGFBPs, 
Ln-1, link protein, myelinbasic, tenascin, ?1AC, ?2M, ?1PI, VN, 
casein, fibrin, fibrinogen, IL1?, IL1?, proTNF? 
MMP-8 collagenase-2  aggrecan, collagen I-III, laminin-5, fibrinogen, substanceP, ?1PI, ?2M, 
MMP-13 collagenase-3  aggrecan, collagens I-IV,VI,IX,X,XIV, fibrillin, FN, gelatin, 
Ln-1, -5, osteonectin, casein, factor XII, ?2M, fibrinogen  
Gelatinases 
MMP-2 gelatinase-A  aggrecan, collagens I,III-V,VII,X,XI, decorin, elastin, entactin, 
fibrillin, FN, fibulins, gelatin, IGFBPs, Ln-1, -5, link protein, myelin 
basic,osteonectin, tenascin, VN, fibrin, ?1AC, ?1PI, fibrinogen, IL1?, 
proTGF?, proTNF?, plasminogen, substanceP 
MMP-9 gelatinase-B  aggrecan, collagens IV,V,XI,XIV, decorin, elastin, fibrillin, gelatin,  
Ln-1, link protein, myelin basic, osteonectin, tenascin, VN, ?2M, ?1PI, 
casein, fibrin, fibrinogen, IL1?, proTGF?, proTNF?, plasminogen, 
substanceP 
Stromelysins 
MMP-3 stromelysin-1  aggrecan, collagens III-V,VII,IX,X,XI, decorin, elastin, entactin,  
fibrillin, FN, gelatin, IGFBPs, Ln-1, link protein, myelin basic, 
osteonectin, tenascin, VN, ?1AC, ?2M, ?1PI, casein, fibrin, 
fibrinogen, IL1?, proTNF-?, plasminogen, substanceP, E-cadherin 
MMP-10 stromelysin-2  aggrecan, collagens III-V, elastin, FN, gelatin, link protein, casein,  
fibrinogen 
Stromelysin like MMPs 
MMP-11 stromelysin-3  IGFBPs, ?2M, ?1PI 
MMP-12 metalloelastase  aggrecan, collagens I,IV, elastin, entactin, fibrillin, FN,gelatin, Ln-1, 
myelin basic, vitronectin, ?2M, ?1PI, factor XII, fibrinogen, proTNF-
?, plasminogen 
Matrilysins 
MMP-7 matrilysin  aggrecan, collagens I, IV, decorin, elastin, entactin, FN, fibulins,  
gelatin, Ln-1, link protein, myelin basic,osteonectin, tenascin, VN, 
?1PI, casein, E-cadherin, fibrinogen, proTNF?, plasminogen 
MMP-26 endometase, matrilysin-2 collagen IV, FN, gelatin, ?1PI, fibrinogen 
Transmembrane type MMPs 
MMP-14 MT1-MMP  aggrecan, collagens I-III, entactin, fibrillin, FN, gelatin, Ln-1,-5, VN,  
?2M, ?1PI, factor XII, fibrin, fibrinogen, proMMP2, proTNF-? 
MMP-15 MT2-MMP  aggrecan, entactin, FN, Ln-1, tenascin, proMMP2 
 MMP-16 MT3-MMP  collagen III, FN, proMMP2 
MMP-24 MT5-MMP   
GPI-type MMPs 
MMP-17 MT4-MMP  fibrillin, FN, gelatin, proTNF? 
MMP-25 MT6-MMP  collagen IV, FN, gelatin, fibrin 
Other MMPs 
MMP-18 collagenase-4 (Xenopus laevis) collagen I 
MMP-19 RASI-1  collagens I, IV, FN, gelatin, tenascin, casein 
MMP-20 enamelysin  amelogenin, aggrecan, Ln-5 
MMP-23 CA-MMP  gelatin 
MMP-28 epilysin  casein 
MMP-21 XMMP 
MMP-22 CMMP 
MMP-27 
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3. Aims and outlines of the study 
 
 
 
3.1 Aims of the study 
 
The aims of this study were to gain a better understanding of the role of MMPs in the progression 
of inflammatory pulpal and periapical diseases, as well as, in the tissue destruction and 
enlargement of odontogenic cysts and PLC. In this study, I have concentrated on the in vivo 
presence of collagenases and gelatinases in pulp, periapical tissue, odontogenic cysts and PLC 
tissue, as well as on their regulation in cell cultures in vitro. I have also studied the changes in the 
collagenase levels during RTC in order to better understand the role of these enzymes in the 
healing process of periapical inflammatory changes. 
 
 
 
3.2 Outlines of the study 
 
1. To determine the in vitro expression and regulation of collagenase-2 (MMP-8) in pulp cells 
and mature odontoblasts.  
 
2. To study the presence, levels and molecular forms of MMP-8 in pulpal and  periapical 
inflammation, and the changes in the concentrations, activation and molecular forms of MMP-
8 in root-canal exudates during root-canal treatment. 
 
3.  To clarify the differences in the in vivo expression of Ln-5, collagenases (MMP-8 and MMP- 
13) and gelatinase (MMP-2) in different odontogenic jaw cysts and their possible role in the 
enlargement and tissue destruction caused by these cysts. 
 
4.  To study the expression of collagenases (MMP-8 and MMP-13) in plasma cells and in plasma 
cell diseases, such as MM and PLC, both in vivo and in vitro and their regulation by 
cytokines, such as IL-6 and TNF-?. 
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4. Materials and methods 
 
 
4.1 Patients and tissue samples 
 
4.1.1 Pulp tissue and odontoblasts (I) 
 
All teeth (n=166) used for the experiments were freshly extracted caries-free third molars 
removed as  part of the normal treatment at the Institute of Dentistry, University of Oulu, Oulu, 
Finland. After sterilizing the tooth and removing the soft tissue and cementum, the root was 
dissected gently close to the cemento-enamel junction. For culturing, the pulp was removed to a 
culture medium and the crowns with odontoblasts were placed in a sterile culture medium. For 
the native mRNA samples, the pulps were gently removed with forceps and placed into 
Eppendorf tubes. The odontoblasts lining the pulp chamber walls were immediately scraped off 
with a sterile excavator and stored at -70?C until analysed.  
For immunohistochemistry, the enamel was cut off to prevent disturbances in sectioning the 
frozen samples. Immediately the enamel was removed with a thin diamond disc under water 
cooling, the teeth were immersed in liquid nitrogen and embedded, and serially cut into 
longitudinal sections on a piece of adhesive tape. The sections were air-dried and fixed in 
methanol, and air-dried again. Then the sections were demineralized and treated with bovine 
testicular hyaluronidase to overcome the masking effect of the matrix proteoglycans and then the 
procedure of immuhistochemical staining was carried out using Vectastain Elite Kit as explained 
later (Vector laboratories, Burlingame, CA, USA) (Table 3). 
 
4.1.2 Patients and diagnosis (II) 
 
10 patients suffering from CAP were selected for the study. The diagnosis was made by clinical, 
and mainly, by radiographic examination, showing the disappearance of the lamina dura and clear 
bone loss in the apical area. All the teeth included into the study were unvital and had only one 
root canal. No controls were used and the one patient excluded from the study had a root fracture. 
Root canal treatment was performed under sterile conditions in three visits (during two-week 
intervals) and the samples from the root canal exudates were collected from the root canals with 
sterile paper points during these visits. The pulpitis tissue specimens for immunohistochemistry 
were collected from patients with irreversible pulpitis when starting normal root treatment 
procedure under sterile conditions. Pulp tissue was gently removed with an excavator to an 
Eppendorf tube containing formalin. 
Specimens from the patients were collected at a private dental clinic with the approval of the 
Ethical Committee of University of Helsinki, Faculty of Medicine, and with permission of the 
patients.  
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Table 3. Tissue specimens 
 
 
Material  Number of   fixation  publications 
  samples      
 
Teeth  166  96%methanol I 
3rd molar    (received fresh) 
Pulpitis  10  10 % buffered II 
    formalin 
Periapical  10  10 % buffered II, IV 
periodontitis   formalin 
      
Radicular cysts 11 (10)  10% buffered III (IV) 
    formalin 
Follicular cysts 11 (10)  10 % buffered III (IV) 
    formalin 
Odontogenic 16 (7)  10 % buffered III (IV) 
keratocysts   formalin 
 
Plasmacytoma 14  10%buffered  IV 
    formalin  
 
 
 
 
4.1.3 Tissue specimens (II, III and IV) 
 
Formalin-fixed and paraffin-embedded samples of chronic apical periodontitis, jaw cysts (RCs, 
FCs and KCs) and PLC, diagnosed histologically according to WHO criteria (Kramer et al 1992, 
Jaffe et al 2001), were used for immunohistochemistry and in situ hybridization (Table 3). These 
tissue specimens were randomly selected from the files of the Department of Oral Pathology, 
Institute of Dentistry, University of Helsinki, Helsinki, Finland, and from the files of the 
Department of Pathology, University of Oulu, Oulu, Finland.  
 
 
 
  4.2 Cells and culture methods 
 
4.2.1. Odontoblasts and pulpal cells (I) 
 
4.2.1.1 Odontoblast  cultures (I) 
The odontoblast culture methods have been described in detail by Tjäderhane et al 1998. For 
odontoblast organ cultures 1.5% (w/v) agarose gel (Agarose NA, Pharmacia Biotech AB, 
Uppsala, Sweden) was mixed into the culture medium (OPTI-MEM I Reduced serum medium 
with antimicrobial element) and was used as embedding material for odontoblast cultures. The 
crowns with odontoblasts lining the pulpal chambers were partially embedded in the agarose gel. 
The pulp chambers were gently washed with culture medium to remove the pulp tissue fluid, and 
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finally filled with the culture medium. The crowns were covered with glass cover slips to prevent 
evaporation from the medium. The medium was also placed on top of the surrounding gel to 
prevent dehydration. 
To study the effects of TGF-?1 on the MMP-8 mRNA expression, odontoblasts and pulp tissues 
were cultured for two days with or without human recombinant TGF-?1. The medium was 
replaced and collected daily. After the culturing procedure the cells were collected and the total 
RNA was isolated as described below. 
 
4.2.1.2 Pulp fibroblast (PF) cultures (I) 
The pulp samples for the human pulp fibroblast (PF) isolation were collected from the teeth that 
were removed as part of the normal treatment of patients. After dissecting the crown with pliers 
(for odontonblast culture), the pulp was gently removed with forceps and the tissue was cut into 
pieces and placed into cell culture clusters containing Dulbecco’s modified Eagle’s medium 
(DMEM) supplemented with foetal bovine serum (FBS) added with an antimicrobial component. 
The explants were then incubated at 37?C, collecting and replacing the medium twice a week. 
The cells were examined daily, and when the fibroblast outgrowth was observed the pulp tissue 
pieces were removed. After reaching the confluence, the fibroblast cell line was established by 
subsequent trypsinization and culturing through several passages. The cells were always allowed 
to reach the confluence before being subcultured. To analyse the MMP-8 mRNA production, the 
PF cells in passage two (n=2) were washed with PBS and the total RNA was isolated as described 
later. 
 
4.2.2 Plasma cells (IV) 
 
Human myeloma cell line RPMI 8226 (ATCC Number: CCL-155; Rockville, MD, USA) was 
cultured in RPMI 1640 medium (Gibco, Basel, Switzerland), supplemented with newborn calf 
serum, lactate glutamate and penicillin-streptomycin. Every third day, the cells were washed in 
phosphate-buffered saline (PBS) and the medium was renewed. After one week the cultured cells 
were separated to receptacles, 9 x 1010 cells in each, and cultured in serum-free culture medium 
for 24 hours. Differently combined cytokines, IL-6, heparin, TNF-?, and PMA, were added to the 
receptacles and after 24 hours the culture medium was centrifuged to separate the cells from the 
medium. About 10 000 cells were counted for the Western blot analysis described later. 
 
4.3 Sample collection from root canals (II)  
 
The RTC was done under sterile conditions using rubber dam isolation. Primary access was done 
with low speed dental burs. The instrumentation of the root canal was started with 20 or 25 files 
and radiograph was taken to measure the working length. A sterile paper point was inserted into 
the canal for 2 minutes to absorb exudates from the canal. The root canals were widened to the 
desired width (minimum 40) with rinsing in between files. For the final rinsing with EDTA and 
NaOCl, the canal was dried before inserting Ca(OH)2 paste for two weeks. After two weeks the 
access was re-opened and the canal was gently instrumented and rinsed with sterile saline 
solution before drying. A sterile paper point was again inserted into the canal for 2 minutes for 
periapical exudate collection.  After two weeks, the same procedure was repeated and afterwards 
the root canal was filled with gutta-percha points and a sealer. After sample collections, the 
exudate from the absorbent points was diluted into a buffer and stored at -70 ˚C for further 
handling. 
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4.4 PCR analysis 
 
4.4.1 RNA isolation (I and IV) 
 
The total RNA was isolated from odontoblasts (native and cultured), pulp tissue cultures and pulp 
fibroblasts cultures, as well as from cultured RPMI 8226 myeloma cells using the Trizol® (Gibco 
BRL, Roskilde, Denmark) reagent isolation method.  The RNA yield was measured by 
absorbance of 260 nm, and the samples were stored at -70˚C until needed. RNA isolated from 
bone marrow cells (Hanemaaijer et al 1997) served as positive controls. 
 
4.4.2 RT-PCR (I, III and IV) 
 
For cDNA synthesis, a 20 ?l reverse transcription reaction was carried out on 2 ?g (plasma cells) 
and 1.7-11 ?g (odontoblast and pulp cells) of the total RNA and random hexamer primers with 
SuperscriptTM II RNaseH-Reverse Transcriptase (Gibco BRL, Roskilde, Denmark) according to 
the product protocol. Specific primers for MMP-8 (not recognizing MMP-1 or other MMPs) were 
those designed as described by Hasty et al (1987). MMP-8 sense primer 5´-
AAGGCAACCAATACTGGG, and MMP-8 antisense primer 5´-ATTTTCACGGAGGACAGG, 
with the expected product size of 522 base pair (bp), and MMP-8 nested sense primer was 5'-
AGCAGCGTCCAAGCAATTG-3' and MMP-8 nested antisense primer 5'-
AATGCATGCTGAACTTCCCTTC-3', with the expected product size of 352 bp. Specific 
primers for MMP-13 were designed based on the published DNA sequence (Freije et al 1994), 
MMP-13 sense primer 5'-AGATAAGTGCAGCTGTTCAC and MMP-13 antisense primer 5'-
TCATTGACAGACCATGTGTC, with the expected product size of 572 bp. MMP-13 nested 
sense primer was 5'-AGCATCTGGAGTAACCGT-3' and MMP-13 nested antisense primer 5'-
TCAATGTGGTTCCAGCCA-3', with the expected product size of 238 bp. 18S ribosomal RNA  
was used as a control for the RNA integrity using primers designed based on the published 
sequence (McCallum et al 1985).   
PCR amplification reactions were performed with primers and DynazymeTM DNA polymerase 
(Finnzymes Oy, Espoo, Finland) according to the product protocol and the linear area of the PCR 
reaction for each reaction was defined. The original amplification was performed as described by 
Hanemaaijer et al (1997). MMP-8 PCR amplification was done at 30-55 cycles and the nested 
MMP-8 PCR amplification was performed using 14-18 cycles, and MMP-13 PCR had 35 or 45 
cycles and the nested 21-24 cycles. 18S PCR was done using 13 or 14 cycles. After finding the 
linear portion of each set of primers for the quantitation of the products, they were quantitated 
with ScionImage program. Values for MMP-8 and -13 cytokine inductions were calculated from 
the scanned densitometric values and related to the corresponding 18S values.  
 
 4.5    Southern blotting (I) 
 
PCR products were fractionated on 1.5 % agarose gels, transferred to a nylon filter (Amersham, 
Buckinghamshire, UK) and hybridized as described elsewhere (Ausubel et al 1988). The specific 
cDNA probe for MMP-8 was prepared. The Southern filter was hybridized to a labelled MMP-8 
cDNA probe in ExpressHyb hybridization buffer (Clontech, Palo Alto, CA, USA) for 1 hr at 
60˚C.  The filters were washed in saline-sodium citrate (SSC)/ sodium dodecyl sulphate (SDS) at 
room temperature and exposed to x-ray film (Kodax X-OMAT).  
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4.6   Western immunoblotting and MMP-8 immunofluorometric assay  
(IFMA) 
 
4.6.1 Western immunoblot analysis (I, II, and IV) 
 
The molecular forms of MMP-8 and -13 were analysed by the Western blotting method utilizing 
the specific MMP-8 antibody (Hanemaaijer et al 1997) and specific polyclonal MMP-13 
antibody (Freije et al 1994). The dissolved plasma cells, supernatant from the plasma cell culture, 
pure RPMI L-glutamine media and the root canal exudate samples were parallel treated with 
Laemmli´s buffer without reducing reagents. To investigate the secretion of MMP-8 into the 
odontoblast and pulp cell culture medium and the effect of TGF-?1 on the amount of secreted 
protein, a conditioned serum-free OPTI-MEM medium, with and without TGF-?, was used for 
the Western blot analysis. To investigate the secretion of MMP-8 into the odontoblast culture 
medium and the effect of TGF-?1 on the amount of secreted protein, a conditioned serum-free 
OPTI-MEM medium, with and without TGF-?, was used for the Western blot analysis. 
The samples were run on polyacrylamide gels by electrophoresis and electrotransferred onto a 
nitrocellulose membrane (Schleicher & Schuell, Dassel, Germany and Bio-Rad Laboratories, 
Richmond, CA, USA) (Hanemaaijer et al 1997). After blocking the non-specific binding sites 
with gelatin or non-fat dry milk (odontoblast and pulp cell samples), the membrane first reacted 
with the primary antibody and then with the alkaline phosphatase-conjugated secondary antibody 
(IV) or peroxidase-conjugated swine anti-rabbit immunoglobulins (I, II). The immunoreactive 
proteins were visualized by Nitro Blue Tetrazolium and 5-bromo-4-chloro-3-indolyl-phosphate or 
with diaminobentzidine tetrahydrochloride (DAB) and quantitated by the Imaging Densitometer 
(Prikk et al 2002). 
 
4.6.2 MMP-8 immunofluorometric assay (IFMA) (I, II) 
 
The concentration of the monoclonal MMP-8 secreted into the odontoblast and pulp tissue culture 
media, as well as the root canal exudate, was determined by a time-resolved immunofluorescence 
assay as described previously (Hanemaaijer et al 1997, Sorsa et al 1999).  Conditioned culture 
medium samples, both with and without TGF-?1, were collected from the odontoblast organ and 
pulp tissue cultures. The monoclonal MMP-8 specific 8708 and 8706 antibodies were used as a 
catching antibody and the tracer antibody, the tracer antibody being labeled using europium 
chelate. Samples were diluted and incubated in assay buffer followed by incubation with the 
tracer antibody. An enhancement solution was added, and fluorescence was measured using a 
1234 Delfia Research Fluorometer (Wallac, Turku, Finland). The monoclonal MMP-8 antibody 
specificity corresponded to that of the polyclonal MMP-8 antibody (Hanemaaijer et al 1997). 
 
4.7 Preparation of RNA probes (III, IV) 
 
For the preparation of RNA probes, an 845 bp PstI-EcoRI fragment of clone L15 of the Ln-5 ?2 
chain was subcloned into the pSP64 and pSP65 vectors in the sense and antisense orientations 
(Kallunki et al 1992). A 635 bp Sca I-Sac I fragment of human MMP-2 cDNA clone was 
subcloned into the M13 polylinker site of the pSP64 and pSP65 vectors (Huhtala et al 1990). A 
734 bp BamHI-HindIII fragment of human MMP-13 cDNA (Freije et al 1994) was ligated into 
the pGEM-4Z vector, and a 95 bp HindIII –BamHI fragment of human MMP-8 cDNA (Hasty et 
al 1990) was ligated into the pGEM-3Z vector. The probes were tested by Northern hybridization 
for specificity and by sequencing. The vectors were linearized with a suitable restriction enzyme 
and a riboprobe transcription kit (Boehringen Mannheim, Germany) was used for transcription. 
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The transcripts were labelled with digoxigenin (DIG)-11-UTP for in situ hybridization, and a 
corresponding sense probe was used as a control for nonspecific hybridization. 
 
4.8  In situ hybridization  (III and IV) 
 
For in situ hybridization, all the solutions were treated with 0.1% diethylpyrocarbonate (DEPC). 
Paraffin sections from different odontogenic jaw cysts were processed prior to prehybridization, 
and in situ hybridization with DIG-labelled RNA-probes was done as described by Mäkelä et al 
(1999). The prehybridization buffer was removed and hybridization buffer containing 800 ng/ml 
DIG-labelled antisense or sense probe was applied to each section and hybridized overnight at 
57?C. The posthybridization washes were done under stringent conditions as described by 
Mäkelä et al (1999). After washing, the sections were blocked and incubated with 1:100 diluted 
alkaline phosphatase-conjugated anti-DIG Fab-fragments and stained with alkaline-fosphatase 
substrate Fast Red (Boehringen Mannheim, Germany) and counterstained with Mayer’s 
haematoxylin (Merck KgaA, Darmstadt, Germany). 
 
4.9 Immunohistochemical staining and evaluation of the staining  
 
4.9.1 Immunostaining (I, II, III and IV) 
 
Immunohistochemistry was performed with different antibodies (Table 4) using 
VECTASTAIN® Elite ABC Kit (Vector Laboratories, Burlingame, CA, USA) according to the 
protocol. The fresh teeth preparates were fixed in methanol and demineralized in EDTA. Before 
immunohistochemical staining, they were pre-treated with bovine testicular hyaluronidase 
(Sigma, St. Louis, MO, USA) and methanol. Formalin-fixed paraffin sections were 
deparaffinized, hydrated, pre-treated with pepsin and with H2O2 in methanol. Thereafter, all the 
sections were incubated with normal goat / horse serum, secondly with primary antibody, and 
then with biotinylated anti-rabbit / anti-mouse immunoglobulin G and with avidin-biotin 
complex. The sections were stained with 3-amino-9-ethylcarbazole (AEC) with the DAB Kit 
(Vector Laboratories, Burlingame, CA, USA) and counterstained with the Mayer’s hematoxylin. 
 
4.9.2 Evaluation of immunostaining (III)  
 
The staining positivity and intensity of different MMPs in the basement membrane zone in the 
different types of odontogenic cysts was analysed using a modification of the method described 
by Bachmeier et al (2000).  Briefly, ten randomly selected areas of two different microscopic 
slides of each cyst type were inspected with a light microscope using 200 x magnification. The 
length of the basement membrane zone observed in each area was 0.65 mm. A two step score was 
used for the positivity of staining (0: no positive staining, 1: positive staining). When staining 
was observed, the intensity was graded using a three-step scale (1: faint, 2: moderate, 3: strong 
positive staining). The results of the 20 independently inspected areas were summarized.  
 
 
 
 
 
 
 
 39
Table 4.  Antibodies used in immunohistochemistry 
   Poly: polyclonal, Mono: monoclonal  
 
Antibody dilution fixation of target pre-treatment publications 
(Ref. of source)  tissue 
    
MMP-8 (Poly) 1:350 96% cold methanol testicular  I 
(Hanemaaijer et al 1997)    hyaluronidase 
MMP-8 (Poly) 1:500- 10% formalin pepsin   II, III, IV  
(Hanemaaijer et al 1997)  1:800 
MMP-13 (Poly) 1:1000- 10% formalin pepsin  III, IV 
(Golub et al 1997) 1:1300 
MMP-2 (Poly) 1:1000 10% formalin pepsin  III 
(Westerlund et al 1996) 
Laminin-5 (Poly) 1:400 10% formalin pepsin  III 
(Salo et al 1999) 
CD68 (Mono) 1:60 10% formalin pepsin  II 
(NeoMarkers, Fremont, Ca, USA) 
NCL-PC (Mono) 1:300 10% formalin pepsin  IV 
(Novocastra, Newcastle-upon-Tyne, UK) 
       
 
 
 
4.10 Statistical analysis (II, III and IV) 
 
To analyse the MMP-8 difference in the root canal exudate during root canal treatment visits the 
Kruskall-Wallis 1-way ANOVA and Mann-Whitney U-test were used (II). The non-parametric 
tests were used because of the absence of the normal distribution within each sample site group. 
The student’s t-test was used when comparing the latent and active MMP-8 levels in the root 
canal exudate (II). To examine statistically the differences of the MMPs in the BM area between 
different odontogenic cysts, the Fisher’s nonparametric exact test was used (III). The MMPs in 
plasma cells in different bone destructive lesions were analysed using the Chi-square test. A p-
value less than 0.05 was considered significant (IV). 
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5. Results 
 
5.1 Pulpal and periapical tissue 
 
5.1.1  MMP-8 in odontoblasts and pulp tissue 
 
5.1.1.1 Healthy pulp tissue (I) 
Expression of MMP-8 mRNA 
In healthy pulps from extracted third molars, the native and cultured odontoblasts and pulp tissue, 
as well as the cultured pulp fibroblasts, expressed MMP-8 mRNA by RT-PCR. The transcripts 
were identical to those from the positive control (bone marrow cells). The specificity of the PCR 
amplification was confirmed by a Southern blot analysis using a specific MMP-8 cDNA probe. 
TGF-?1 added to the cell culture down-regulated 10% and 25% the MMP-8 mRNA production in 
odontoblast and pulp tissue cultures. 
Expression of MMP-8 protein  
A Western blot analysis with MMP-8 antibody detected a 65 kDa immunoreactive band in all the 
native odontoblast, pulp and pulpal fluid samples from sound teeth. A fainter 50 kDa band was 
also detected in all the pulp and pulpal fluid samples, as well as from the conditioned odontoblast 
culture medium. A high molecular weight band (>100-112 kDa) of MMP-8 was detected in all 
the native samples. No characteristic PMN MMP-8 (75-80 kDa) isoform was observed. TGF-?1 
had no observable effect on the MMP-8 level in the samples studied by the Western blot analysis. 
However, in the PCR analysis of secreted MMP-8 from the culture medium of odontoblasts and 
pulp tissue revealed a detectable down-regulation in the MMP-8 levels when TGF-?1 was added. 
The medium was collected after 24 and 48 hours of culturing.  The MMP-8 levels in the 
odontoblast and pulp tissue medium were lower in both (24 and 48 h) samples cultured with 
TGF-?1.  
Immunohistochemical staining with the same MMP-8 specific antibody revealed MMP-8 
positivity in the odontoblast cell layer, localised to the odontoblast body. MMP-8 positivity was 
also detected in some, but not all, endothelial cells lining the pulp vessels. 
 
5.1.1.2 Pulp with inflammation (II) 
Expression of MMP-8 protein  
The Western blot analysis of the pulpitis tissue revealed intensely stained bands of 55-45 kDa, 
75-80 kDa and 100-112 kDa. The 75-80 kDa band most likely represents the MMP-8 isoform 
from the PMNs. By immunohistochemistry, in addition to PMN cells, MMP-8 immunoreactivity 
was detected in the macrophage-like cells, plasma cells and some endothelial cells. The 
immunohistochemical analysis revealed that MMP-8 immunoreactivity accumulated around the 
pulp abscess. 
 
5.1.2 MMP-8 in the root canal exudate (II) 
 
RTC clearly decreased the MMP-8 levels in the root canal exudate. However, in order to 
successfully minimize the MMP-8 concentration in the root canal exudate, the local calcium 
hydroxide paste medication was required for four weeks. After careful mechanical and chemical 
root canal preparation with local adjunctive medication for a fortnight, some MMP-8 could still 
be detected in some cases.  
There was a statistically significant difference in the MMP-8 levels between the first and last root 
canal therapy visits (Kruskall-Wallis p=0.02; Mann-Whitney U-test p=0.0107). 
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The high (65-75 kDa) and low (45-55 kDa) molecular size MMP-8 isoforms detected in the root 
canal exudates were in both latent and active forms. If there was MMP-8 detectable in the root 
canal exudate during the second visit, the relative amount of the active form was elevated, but not 
significantly.  The only case in which the MMP-8 level in the root canal exudate did not decrease 
during the root canal treatment, was later diagnosed to have a vertical fracture and the tooth 
needed to be extracted. 
 
5.1.3 MMPs in apical periodontitis (II) 
 
In CAP, MMP-8 was immunohistochemically detected mostly in the PMNs. In addition to the 
PMNs, MMP-8 protein was present in the subpopulation of macrophages and plasma cells. The 
histiocytic nature of the macrophages was confirmed by staining with the CD68 macrophage cell 
marker. NCL-PC positive plasma cells expressed MMP-8 in 2 out of 10 cases. In addition to the 
plasma cells MMP-13 protein expression was present in macrophages. Half of the samples 
studied expressed MMP-13 protein in the plasma cells and the MMP-13 mRNA expression was 
evidenced by in situ hybridization. 
 
5.2  Odontogenic cysts 
 
5.2.1 Laminin-5 (III) 
 
The ?2 chain of Ln-5 was detectable by immunohistochemistry in the BM zone of all the RC, FC 
and KC samples studied. In the KC samples, the ?-2 chain stained the basement membrane zone 
as a continuous ribbon. In 30% of the cases, a few epithelial cells stained positively. In the FCs, 
the Ln-5 ?2 chain staining showed local breaks in the basement membrane zone in 64% of the 
cases. In the epithelial cells, ?2 chain positivity was present in 81% of the cases. In the RCs, the 
BM zone staining with the Ln-5 ?2 chain antibody showed local breaks in 18% of the cases and 
the epithelial cells showed ?2 chain positivity in 91 % of the cases. Expression of Ln-5 ?2 chain 
mRNA was observed in all cyst types in basal epithelial cells. 
 
5.2.2 Expression of MMP-2 (III) 
  
MMP-2 immunoreactivity was detected in the cyst capsule fibroblasts of all the cyst types studied 
(RC, FC and KC), and mRNA was also detected in some fibroblast-like cells of all the cysts. 
Only the KCs showed MMP-2 immunoreactivity in all the samples studied. MMP-2 protein 
expression was detected in the epithelium in all the cyst types studied, but clear expression of 
MMP-2 in basal cells and the BM zone was only in the detached epithelium of the KCs. There 
was a statistical difference in the location of the MMP-2 expression in the BM area between the 
KC and RC (p=0.023). The difference was clear but not statistically significant between the KC 
and FC (p=0.0698). The quantity and intensity of the MMP-2 staining in the BM area was clearly 
higher in the KCs than the other cyst types studied. 
 
5.2.3 Expression of MMP-8 (III, IV) 
 
MMP-8 immunoreactivity was detected in all the cyst types studied, mainly in the connective 
tissue cyst capsule. PMNs, plasma cells and FC foam cells (phagocytic macrophages) expressed 
MMP-8. In the epithelium, MMP-8 protein was observed in the FC goblet cells. Plasma cells in 
the FCs (6/10) stained more often positively with MMP-8 antibody than those in the RCs (2/10) 
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and KCs (1/7). MMP-8 mRNA was detectable in plasma cells and foam cells, as well as in 
epithelial goblet cells and some epithelial cells of the FCs. In the FCs both protein and mRNA of 
MMP-8 could be observed in the same plasma cell accumulation. Interestingly, MMP-8 
expression appears to be seen in the FCs more often than in the other (RC and KC) cyst types. 
 
5.2.4 Expression of MMP-9 (unpublished results)   
                                     
MMP-9 was expressed by PMNs in cyst capsules and infiltrating in the epithelium, and cyst 
capsule plasma cells in KCs and RCs. MMP-9 mRNA was detected in osteoclasts in the bony 
front of cyst capsule. MMP-9 expression was not detected in the jaw cyst lining epithelial cells. 
 
5.2.4 Expression of MMP-13 (III, IV) 
 
MMP-13 protein was observed in all the KCs. MMP-13 positivity could be observed in the 
plasma cells of theKC cyst capsule close to the lining epithelium and in the epithelial cells, as 
well as in small satellite cyst epithelial cells in the cyst capsule. In 55% of the KCs, MMP-13 
expression was detectable in the BM zone. In the RCs, the number of positive cases was about 
half that observed in the KCs. MMP-13 mRNA was present in the plasma cells and  epithelial 
cells of the KCs and in some cyst capsule fibroblasts as well. Statistical analysis showed a 
significant elevation in MMP-13 expression in KC plasma cells compared to the RCs and FCs. 
When comparing the epithelial expression, a significant difference was detected between the KCs 
and FCs (p=0.0294), but not between the KCs and RCs (p=0.6372). The quantity and intensity of 
MMP-13 immunostaining was clearly higher in the KCs than in the FCs and RCs. 
 
 
5.3 Multiple myeloma and plasmacytoma 
 
5.3.1    Plasmacytoma tissue samples (IV) 
 
5.3.1.1 MMP-8 
In the PLC tissue samples, MMP-8 expression was only slightly observable by 
immunohistochemistry, but in situ hybridization was negative. 
 
5.3.1.2 MMP-13 
Clear MMP-13 immunoreactivity was detected in 80% of the PLCs (no expression was detected 
in one tonsil, as well as the bone marrow and tongue PLC samples). Statistical analysis revealed 
significantly enhanced MMP-13 expression in the PLC samples in comparison to the RC and FC 
samples. No significant difference was detected when compared with the KCs. Of the three 
samples studied by in situ hybridization, MMP-13 mRNA expression was revealed in malignant 
PLC plasma cells in bone marrow and the upper jaw mucous membrane, but not in the vertebral 
lesions. 
 
5.3.2 Multiple myeloma cell cultures (IV) 
 
We studied the MMP production in vitro in the human myeloma cell line RPMI 8226. The cells 
were treated with PMA, cytokines (IL-6 and TNF-?) or heparin, alone or in different 
combinations. The results were analysed by RT-PCR and Western blotting. 
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5.3.2.1  MMP-8 expression 
MMP-8 mRNA and protein was observed in cultured RPMI plasma cells. By Western blotting 
clear immunoreactive bands were detected in the cell lysates, but not in the culture media. MMP-
8 immunoreactivity was clearly enhanced by IL-6 alone and combined with TNF-?.  A 
combination of heparin with cytokines and PMA further induced MMP-8 immunoreactivity. 
MMP-8 mRNA expression was also increased by PMA, TNF-? and IL-6 in cultured RPMI 8226 
cells. In 24 hours the MMP-8 mRNA was upregulated by 9.1 (PMA), 4.7 (TNF-?) and 7.2-fold 
(IL-6).  The MMP-8 induction was more clearly presented in the RT-PCR than in the Western 
blot, probably due to a delay in protein expression. 
 
5.3.2.2  MMP-13 expression 
The RT-PCR and Western blot showed MMP-13 expression in the RPMI 8226 malignant plasma 
cell line. Detected by the RT-PCR PMA, TNF-? and IL-6 upregulated the MMP-13 mRNA 
expression by 6.1-, 8.7- and 6.8-fold, and the induction was enhanced when the cytokines were 
combined with heparin. MMP-13 protein was detected in the plasma cell lysates but not in the 
culture media. IL-6 alone and combined with TNF-? increased the MMP-13 immunoreactivity. 
Heparin combined with cytokines and PMA also increased the MMP-13 expression slightly. The 
RT-PCR presented increased MMP-13 expression more clearly than the Western blot. 
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6. Discussion 
 
6.1 The role of MMPs in pulpal and periapical tissue and root canal exudate 
 
6.1.1 MMPs in pulp tissue (I, II) 
 
Pulpal cells can express various MMPs, including MMP-1, MT1-MMP, MMP-20 (Llano et al 
1997, Lin et al 2001, Palosaari et al 2002), and MMP-2 (Tjäderhane et al 1998, Chang et al 
2001) in vitro, and MMP-20 in vivo (Sulkala et al 2002). Bacteria and their virulence factors 
(toxins) upregulate MMP-2 expression and secretion by pulp cells (Chang et al 2002). Most of 
the studies done have utilized pulp tissue cells and fibroblasts, but odontoblasts have lacked a 
good in vitro study model. The new odontoblast culturing method described by Tjäderhane et al 
(1998) has provided a new way to reveal molecular events and processes associated with the 
healthy and diseased pulp and its cellular components. As recently shown, odontoblasts can 
express different MMPs: MMP-2, -9, -20 and MT1-MMP (Llano et al 1997, Tjäderhane et al 
1998, 2001, Palosaari et al 2002), and, according to the present results, MMP-8 as well (I). TGF-
? can upregulate MMP-9 expression, and down-regulate MMP-2 synthesis (Tjäderhane et al 
1998), but has no effect on collagen synthesis in odontoblasts (Palosaari et al 2001). The present 
study further revealed that TGF-? has a reducing effect on MMP-8 synthesis in mature 
odontoblasts (I). TGF-? is a multifunctional growth factor found in dentin, and it is thought to 
regulate tissue repair in the tooth (Lesot et al 1994). The downregulation of MMP-8 may be a 
factor leading to a reparative dentin formation because it is regarded as essential for modulating 
tissues during normal dentin formation. It is evident that MMPs expressed by odontoblasts may 
have a role in dentin and reparative dentin formation and the growth factors can act as MMP 
regulators, as well as regulate collagen synthesis.  
A strong expression of MMP-8 in the inflammatory cells of pulpitis tissue was seen. Studies have 
shown that bacteria and their products upregulate MMP-1 and MMP-2 in pulp cells, but have no 
effect on MMP-9 (Nakata et al 2000, Chang et al 2002). The levels of MMP-1, -2, and –3, 
expressed mainly by monocyte/macrophages and fibroblasts, are significantly higher in acute 
pulpitis tissue than in healthy pulp tissue (Shin et al 2002). Bacterial products irritate PMNs to 
release MMP-8 (Ding et al 1996, 1997), and proinflammatory cytokines upregulate MMP-1 and 
MMP-2 in the pulpal tissue (Tamura et al 1996, O’Boskey et al 1998, Chang et al 2001). The 
bacteria and their products may act in pulpal inflammation by upregulating cytokine production 
and via the cytokine pathway increase MMP expression and directly irritate cells to produce 
MMPs. The MMP-8 in pulpal inflammatory lesions was mainly of PMN origin. PMNs are cells 
forming pulp abscesses and, thus, activated MMP-8 may well participate in the tissue destruction 
of pulp necrosis and abscesses. PMNs are migrating and recruiting cells able to penetrate dentinal 
tubules (Bergenholtz 2000), and they may well need MMP-8 for this. Western blot bands 55-45 
and 100-112 kDa probably represent the MMP-8 isoform originating from the non-PMN lineage 
cells (Hanemaaijer et al 1997). MMP-8 species higher than 90 kDa possibly represented high 
molecular size MMP-8 complexes formed after binding to inhibitors (TIMPs, ?2M) and/or 
dimerization (Prikk et al 2001, 2002). 
 
6.1.2 MMPs in periapical tissue and root canal exudate (II, IV) 
 
Untreated tooth necrosis usually leads to CAP, a destructive inflammatory condition around the 
tooth apex. It is a complicated process including bacteria and their products, immunoglobulins, 
proinflammatory cytokines and other inflammatory mediators affecting each other in a complex 
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manner. PMNs, being the first cellular barrier to bacterial invasion, may, in addition to digesting 
bacteria, destroy surrounding tissue compartments by secreting MMPs, especially MMP-8. PMN 
cells, induced by bacterial products or toxins, can release proinflammatory cytokines (Barkhordar 
et al 1992) which autocrinically stimulate PMNs to release MMP. Plasma cells, which enter the 
inflammatory tissue after the PMNs, secrete immunoglobulins and also express MMP-8 and 
MMP-13 (IV). Macrophages are the major inflammatory cells in CAP. They take part to PMN 
and lymphocyte activation and are considered to be the major source of IL-1?, IL-1? and TNF-?. 
MMP-1, -2 and -3 immunoreactivity has been detected in the inflammatory cells (plasma cells, 
lymphocytes and macrophages) of periapical lesions (Shin et al 2002). Monocytes/macrophages 
express MMP-8 and MMP-13 (Prikk et al 2001, Kiili et al 2002), and these MMPs may work not 
only extracellularly taking part in tissue destruction, but also intracellularly in the phagocytic 
process. The osteoclasts are responsible for gnawing the bone at the periphery of CAP (Bohne 
1990, Anan et al 1991). This ”bony digestion” can well be, at least partially, due to MMPs, 
especially by MMP-9 secreted by osteoclasts (Reponen et al 1994, Wucherphennig et al 1994). 
Being able to activate proMMP-9, MMP-13 (Knäuper et al 1997) has the potential to act as a 
proMMP-9 activator in CAP. The MMPs secreted by cells other than osteoclasts in CAP may, 
thus, be responsible for the degradation of the ECM particles and the waste products appearing 
after osteoclast bone dissolution during CAP formation. 
The inflammatory process and tissue destruction in CAP, at least in part, resembles the same 
phenomenon in periodontitis provoked by putative periodontopathogenic bacteria (Ding et al 
1996, 1997). The oral bacteria trigger MMP release and activation by the PMN cells (Ding et al 
1997) and in periodontitis the MMPs, and especially their activation, have a pivotal role in 
periodontal tissue destruction and are considered to be a key biochemical marker of active 
periodontal disease (Sorsa et al 1994, 1995, 1999, Ingman et al 1996, Tervahartiala et al 2000, 
Kiili et al 2002, Mäntylä et al 2000, 2003). It is likely that in addition to other bone destructive 
mechanisms present (Fig. 2), the MMPs exert a destructive role in CAP as well (II, IV). 
The main focus of RCT in CAP is to eliminate the bacteria, their virulence factors and toxins and 
associated inflammatory reaction in the apical area. As a result, bacteria and their products no 
longer continue the inflammatory process and the level of inflammatory cells diminishes. RCT, 
by eventually reducing the infective bacteria and the apical inflammatory reaction, diminishes the 
active and latent forms of MMP-8 in the root canal exudates and, thus, the MMP-8 dependent 
inflammatory tissue destruction in apical area is also decreased (II). Finding of MMP-8 in the 
root canal exudate even after the root canal was cleaned by chemical and mechanical means 
shows that the MMP-8 must be of periapical origin and that the inflammatory process in the 
apical area is diminishing slowly but clearly during three weeks (II). Detection of decreased 
MMP-8 levels during RCT may lead to adjunctive chair-side or point-of-care diagnostic tools 
similar to the one developed for periodontitis GCF and peri-implant sulcular fluid (PISF) (Sorsa 
et al 1999, Kivelä-Rajamäki et al 2003, Mäntyla et al 2003) to evaluate the periapical 
inflammation process during RCT (II). In this regard, chemical compounds, such as clorhexidine, 
often used as adjunctive medication in the periapical, as well as in periodontal, treatment in 
addition to its antimicrobial properties, exert properties directly in vitro and in vivo to inhibit the 
MMPs and their oxidative activation including MMP-8 (Sorsa et al 1990, Gendron et al 1999, 
Azmak et al 2002, Mäntyla et al 2003). 
 
   6.2   MMPs and Ln-5 in odontogenic cysts (III, IV) 
 
KC is the most aggressive bone destructive odontogenic jaw cyst with a strong tendency to recur. 
This is considered to be mainly due to the epithelial detachment. KC epithelium also proliferates 
rapidly compared to other odontogenic cysts. Many MMPs have been detected in odontogenic 
jaw cyst tissue extracts and cultured cyst cells, but so far only MMP-1 has been located on the 
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cellular level to the cyst epithelium (Lin et al 1997). In addition, KC epithelial cells in culture 
have been shown to secrete proMMP-9 and proMMP-3 (Kubota et al 2000). Certain MMPs, such 
as MT1-MMP, MMP-2 and MMP-13 are able to process the Ln-5 ?2 chain (Giannelli et al 1997, 
1999, Koshikawa et al 2000, Pirilä et al 2001b, 2003). Epithelial cell migration and detachment 
from the BM zone is regulated partially through Ln-5 processing (Giannelli et al 1997, 1999, 
Koshikawa et al 2000, Gilles et al 2001). Pirilä et al (2003) have recently shown that MMP-3, -8, 
-12, -14 and –20 can process Ln-5. However, only the processing of the ?2 chain by MT1-MMP, 
MMP-2 and MMP-13, but not MMP-8, induces epithelial cell migration (Giannelli et al 1997, 
1999, Pirilä et al 2003). In KCs, the ?2 chain of Ln-5 was co-located with MMP-2 and –13 in the 
BM zone (III). In other cysts (RC, FC) the MMPs studied did not localize to the BM zone (III). 
These co-localization results in KCs indicate that particularly MMP-2 and –13 and Ln-5 may be 
involved in the specific molecular processes in the KC epithelium. By splitting the Ln-5 ?2 chain, 
they may evoke epithelial proliferation and migration in KCs. MMP-2 and MMP-13 can also 
cleave collagen IV, the Ln-5 binding site in BM, and MMP-2 also cleaves the anchoring filament 
type VII collagen (Rousselle et al 1997). MMP-2 expression is particularly strong in the BM of 
KCs when epithelial detachment occurs. This suggests that MMP-2 has a role in the loosening of 
the KC epithelium caused by Ln-5 degradation and maybe collagen VII breakdown. MMP-13, 
together and activated by MMP-2, could contribute to the epithelial migration and growth 
induced by Ln-5 and collagen IV cleavage.  
The localization of MMP-8 in the FC cyst epithelium, but not in the BM zone, fits the less 
aggressive clinical outcome of FCs. The presence of MMP-8 in secreting cells (goblet cells) 
suggests that goblet cell-derived MMP-8 contributes to the dissolution of the cyst lumen material 
and eventually affects the osmotic pressure. MMP-9 expression was not detected in epithelial 
cells either by immunohistochemistry or in situ hybridization, although the epithelial cells of KCs 
produce pro-MMP-9 in cell culture (Kubota et al 2000). Instead, MMP-9 was detected in plasma 
cells and PMNs invading in the cyst epithelium probably targeting the cyst lumen. MMP-8 
positive PMNs were also detected between the epithelial cells in odontogenic cysts. 
Earlier studies have shown MMP-1, MMP-2, MMP-8 and MMP-9 in jaw cyst fluids and tissue 
extracts (Teronen et al 1995a, b, Kubota et al 2000), and MMP-2 together with MT1- MMP has 
been found in cultured KC fibroblasts (Kubota et al 2002). MMP-1 is also detected in fibroblasts, 
endothelial cells and osteoblasts in RCs (Lin et al 1997). In addition to the cyst epithelium, the 
investigation revealed the presence of MMP-2, -8 and -13 in cyst capsule cells, mainly 
fibroblasts, and in inflammatory cells, PMNs and plasma cells.  
The expression of different bone resorption stimulative cytokines (IL-1?, TNF-?) and 
prostaglandins is also found in odontogenic cysts (Meghji et al 1996, Li et al 1997). Thus they 
may well act as MMP up-regulators during the growth and expansion of cysts. For example, IL-1 
adds, collagen I induced, MT1-MMP production and proMMP-2 activation in KC fibroblasts 
(Kubota et al 2002). Osteoclasts are the front line cells in bone resorptive areas (Formigli et al 
1995), and MMP-9 mRNA was present in osteoclasts in the bony front of the cyst capsule. MMP-
2 mRNA was mainly detected in the fibroblast-like cells (III). Thus, MMP-2 could mainly be 
taking part in ECM modulation within the cyst capsule, while MMP-9 might be involved in the 
osteoclastic bone dissolution. MMP-8 and MMP-9 protein was present in PMNs in the cyst 
capsule in all cyst types studied. MMP-8 and MMP-9 containing PMNs are able to invade the 
whole cyst capsule and epithelium possibly enhancing the levels of these MMPs in the cyst 
lumen fluid, where they have also been previously detected (Teronen et al 1995a, b,  Kubota et al 
2000). Plasma cells were able to express MMP-8, -9 and -13, although MMP-13 was mainly 
found in the KC plasma cells. MMP-13 is closely connected to tumours and malignancy (Kähäri 
and Saarialho-Kere 1999) and KCs are partly regarded as benign neoplasm (Shear 2002a). Thus, 
it is tempting to speculate that catalytically competent and efficient MMP-13 strengthens the 
suggested neoplastic nature of KCs (Shear 2002b, c). In fact, MMP-13 might, at least partially, 
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explain the special growth pattern of KCs both by efficiently degrading the epithelium and the 
BM, as well as dissolving the connective tissue underneath. 
 
6.3     MMPs in multiple myeloma (IV) 
 
MM and PLC are bone destructive lesions where the bone tissue is replaced by malignant 
monoclonal plasma cells (Neville et al 2002). The expression of both MMP-13 mRNA and 
protein in the malignant plasma cells of plasmacytoma specimens was evident (IV), and MMP-13 
is expressed in other malignancies as well (Airola et al 1997). Thus MMP-13 might participate in 
the destruction of normal tissue in order to allow the growth of malignant cells (Thomas et al 
2000). The growth of MM is affected by various cytokines, of which IL-6 is considered to be the 
most important (Sati et al 1998, Lauta 2001). Plasma cells in chronic inflammatory diseases can 
produce other cytokines, such as TNF-? (DiGirolamo et al 1997). MM cells express gelatinases, 
of which MMP-2 is further connected to the increased angiogenic and invasive potential of bone 
marrow plasma cells (Vacca et al 1999) and MMP-7 being also expressed by MM cells is capable 
of activating latent MMP-2 (Barille et al 1999). The secretion of MMP-8 and MMP-13 by 
cultured RPMI 8226 myeloma cells was confirmed and the expression was enhanced by different 
cytokines including IL-6 and TNF-? (IV). In earlier studies, IL-6 has not been detected to affect 
MMP expression. The presence of MMP-13 protein and mRNA in plasmacytoma tissue 
specimens was shown by immunohistochemistry and in situ hybridization. The ability of MM 
cells to express different MMPs, especially the collagenolytic and serpinolytic MMP-8 and 
MMP-13, might be necessary for the invasive and tissue destructive potential of MM. Thus, 
MMP inhibitors including bisphosphonates alone or in combination with other MMP selective or 
broad-spectrum inhibitors or cancer drugs may, in future, be a new putative medication for this 
lethal disease (Derenne et al 1999, Koivunen et al 1999, Teronen et al 2000, Llavaneras et al 
2001, Heikkilä et al 2002, 2003). 
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7.  Conclusions 
 
 
ECM and BM breakdown takes place in many normal and pathological conditions, such as 
inflammation and tumour growth. Collagenases (MMP-1, -8 and –13) and gelatinases (MMP-2 
and –9) are MMPs capable of degrading almost all ECM and BM components. These enzymes 
are known to be effective in various inflammatory and other tissue destructive diseases. 
The study shows the presence of MMP-8 in mature human odontoblasts and pulp tissue and TGF-
?1 reduced the MMP-8 mRNA expression in odontoblastic cell cultures. The MMP-8 detected by 
Western blot was the isoform of non-PMN lineage cells. The presence of MMP-8 in healthy 
odontoblasts and pulp tissue suggests that MMP-8, an efficient inducer of type I collagenolysis, 
may contribute to the modulation of dentin and secondary dentin formation. 
In pulpitis, the MMP-8 was expressed in various inflammatory cells, such as PMNs, 
macrophages, plasma cells and in endothelial cells. In pulpitis, MMP-8 was considered to 
originate from both PMN and non-PMN lineage cells. The main MMP-8 positivity was 
accumulated around the pulp abscess suggesting that it also contributes to the abscess formation. 
In root canal exudates, MMP-8 levels decreased during root canal treatment. Both active and 
latent MMP-8 were detected. Immunohistochemistry revealed MMP-8 in CAP tissue mostly in 
PMNs, but occasionally also in macrophages and plasma cells. MMP-13 was seen in some 
macrophages and plasma cells, a finding also evidenced by in situ hybridization. These results 
allow one to presume that collagenases are actively taking part in the tissue destruction and 
granulation tissue formation in CAP. 
To be able to expand odontogenic cysts need to destroy the bone tissue ahead and their 
epithelium needs to proliferate. A KC is an odontogenic cyst with special characters due to its 
growth and epithelial proliferation manners. Ln-5 is a basement membrane protein being 
connected to both epithelial adhesion and migration. MMP-2, -8 -13 and MT1-MMP cleave Ln-5 
though only MMP-2, -13 and MT1-MMP degrade the Ln-5 ?2 chain into a form able to induce 
epithelial cell migration. Co-localization of Ln-5, MMP-2 and MMP-13 was present in the KC 
basement membrane zone but not in other odontogenic cysts studied.  Based on this it is 
suggested that these MMPs, being able to degrade Ln-5, are partially responsible for the epithelial 
proliferation and detachment of the KC epithelium.  MMP-8 was mainly detected in the goblet 
cells of FC epithelium. In cyst capsules, MMP-2 was detected in fibroblast-like cells, MMP-8 in 
PMNs, plasma cells and foam cells, mainly in FCs. MMP-9 was detected in osteoclasts in the 
bony front and MMP-13 was detected in some fibroblasts-like cells and plasma cells mainly in 
KCs. These findings suggest that both collagenases and gelatinases are active in the cyst 
enlargement and tissue rebuilding in cyst capsule formation. MMP-13 was found mainly in KCs, 
speaking for its neoplastic nature.  
MM and PLC are tissue destructive monoclonal plasma cell malignancies. In order to expand, 
they need to destroy the normal tissue. MMP-8 and MMP-13 expression was detected in MM cell 
cultures and the expression of both was enhanced by cytokines and PMA. In PLC tissue, MMP-
13 expression was detected by immunohistochemistry and in situ hybridization. There was a 
significant difference in the expression of MMP-13 between PLCs and benign cysts and apical 
periodontitis tissues. This confirms the notion of MMP-13 being present and operating especially 
in malignant lesions. 
 
 
 
 
 
 
 49
ACKNOWLEDGEMENTS 
 
 
Laboratory studies of this work were carried out at the Institute of Dentistry, University of 
Helsinki, Helsinki, Finland, Biomedicum Research Laboratory, Institute of Dentistry, University 
of Helsinki, Helsinki, Finland, and the Institute of Dentistry, University of Oulu, Oulu, Finland 
during 1997-2002. I wish to thank Professor Heikki Murtomaa, the former Dean of Helsinki 
University, and Professor Jukka H Meurman, the present Dean of Helsinki University, for placing 
the research facilities at my disposal. The periapical exudates collection took place at a private 
dental clinic: Ala-Malmin Hammaslääkärit, Helsinki, Finland, and I wish to thank Ari 
Kalliomäki, DDS, for giving me the opportunity to collect the samples at his Dental office.  
 
 
I warmly thank my supervisors: Professor Tuula Salo, Professor Timo Sorsa, and associate 
Professor Olli Teronen who opened up the scientific world of matrix metalloproteinases for me, 
together with Professor Jarkko Hietanen who introduced me to the interesting field of oral 
pathology. It was a great pleasure to work with such innovative supervisors. I also owe my 
gratitude to my two “unofficial” supervisors and friends Professor Päivi Maisi (in memoriam) 
and Professor Leo Tjäderhane with whom I shared many creative discussions. The positive, 
encouraging attitude of all my wonderful supervisors was needed to push me through this thesis 
work. Thank YOU!!! 
 
 
I wish to thank my reviewers Associate Professor Tuula Ingman and Professor Ylermi Soini for 
their constructive criticism and thorough reviewing of my thesis. I would also like to express my 
gratitude to Roderick Dixon for revising the language of this work and Helene Javen who 
checked the reference list. 
 
 
My sincere thanks go to all my colleagues and co-workers in the Universities of Helsinki and 
Oulu. Special thanks goes to Emma Pirilä, MSc, and Taina Tervahartiala, DDS, PhD, who helped 
me so much in questions dealing with laboratory work. All the other colleagues, including Nina-
Li Avellan, DDS, Pia Heikkilä, DDS, Anne Järvensivu, DDS, Marjo Kivelä-Rajamäki, DDS, 
Kaiu Prikk, MD, PhD, and Mathias Stenman, DDS, as well as other friends from the Universities 
of Helsinki and Oulu deserve my special thanks too. We have shared so many unforgettable 
moments together and working without you would have been so dull. You made the work joyable 
and full of laughter! Thanks!!     ? 
I also express my gratitude to my other coauthors: Professor Markku Larmas, Hannele Luoto, 
MSc, Heidi Palosaari, DDS, PhD, Meeri Sutinen , MSc, and Anu Väänänen, MSc.  
 
 
The laboratory staff, including “the boss” Kirsti Kari, MSc, Marjatta Kivekäs, Annikki Siren, and 
others, also deserve my gratitude. Their work made it possible for me to carry out the laboratory 
work needed for this thesis. I also thank my cousin Gina Braxenholm for her invaluable help with 
the statistics and I owe my warmest thanks to Assistant Professor Pirjo-Liisa Lukinmaa for her 
“mental tutoring”. I am also grateful to Marjo Kostia for her help in questions dealing with book-
printing.   
My warm thanks go to the staff at the private dental clinic, Ala-Malmin Hammaslääkärit, for 
being so patient with me while I was collecting the root canal samples and during all this time 
they have been so patient regarding my changing working hours. 
 50
 
All my friends and relatives get a big hug from me for being there for me when I needed people 
to talk to, especially Pirjo, Raija, Saila, the two Sirpas, Sussa, and “Pulmuset”. Thank You for 
putting up with me for all these years. Do not stop now!    ? 
 
 
And last but not least, I wish to express my gratitude to the most important people in my life: Ari, 
Ville and Saara. I could not have done this without your love and support.  I love You!     ? 
 
 
This thesis study was supported by the Academy of Finland, the HUCH- and OUCH-EVO grants, 
the Willhelm and Else Stockman Foundation and the Helsinki University Reseach Funds, and my 
personal grants from the Finnish Female Dentist Association and the Finnish Dental Society, 
which I gratefully acknowledge. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 51
 References 
 
Aimes RT, Quiqley JP. Matrix metalloproteinase-2 is an interstitial collagenase. Inhibitor free enzyme 
catalyzes the cleavage of collagen fibrils and soluble native type I collagen generating the specific 3/4- and 
1/4-lenghth fragments. J Biol Chem 1995; 270: 5872-5876. 
Airola K, Johansson N, Kariniemi AL, Kähäri VM, Saarialho-Kere UK. Human collagenase-3 is expressed in 
 malignant squamous epithelium of the skin. J Invest Dermatol 1997; 109: 225-231.  
Ala-Aho R. Human collagenase-3 (MMP-13) in tumor growth and invasion. Dissertation. Turku: University of 
  Turku ; 2002 
Amano S, Akutsu N, Matsunaga Y, Kadoya K, Nishiyama T, Champliaud M-F, Burgeson RE, Adachi E. 
 Importance of balance between extracellular matrix synthesis and degradation in basement membrane 
 formation. Exp Cell Res 2001; 271: 249-262. 
Andrew EM, Plater-Zyberk C, Brown CM, Williams DG, Maini RN. The potential role of B-lymphocytes in the  
 pathogenesis of rheumatoid arthritis. Br J Rheumatol 1991; 30 (Supl 1): 47-52. 
Anan H, Akamine A, Hara Y, Maeda K, Hashiguchi I, Aono M. A histochemical study of bone remodeling 
 during experimental apical periodontitis in rats. J Endod 1991; 17: 332-337. 
Angel P, Karin M. The role of Jun, Fos and the AP-1 complex in cell-proliferation and transformation. 
 Biochim Biophys Acta 1991; 1072: 129-157. 
Apte SS, Mattei MG, Olsen BR. Cloning of the cDNA encoding human tissue inhibitor of metalloproteinase-3 
 (TIMP-3) and mapping of the TIMP-3 gene to chromosome 22. Genomics 1994; 19: 86-90. 
Artese L, Piattelli A, Quaranta M, Colasante A, Musani P. Immunoreactivity for interleukin 1? and tumor necrosis  
factor-? and ultrastructural features of monocytes/macrophages in periapical granulomas. J Endod 1991; 17: 
483-487. 
Atkinson JJ, Senior RM. Matrix metallorpoteinase-9 in lung remodeling. Am J Respir Cell Mol Biol 2003; 28: 12- 
 24. 
   Autio-Harmainen H, Hurskainen T, Niskasaari K, Höyhtyä M, Tryggvason K. Simultaneous expression of 70 
kilodalton type IV collagenase and type IV collagen ? 1(IV) chain genes by cells early human placenta and 
gestational endometrium. Lab Invest 1992; 67: 191-200. 
Azmak N, Atilla G, Luoto H, Sorsa T. The effect of subgingival controlled-release delivery of clorhexidine chip 
on clinical parameters and matrix metalloproteinase-8 levels in gingival crevicular fluid. J Periodontol 2002; 
73: 608-615.  
Bachmeier BE, Nerlich AG, Boukamp P, Lichtinghagen R, Tschesche H, Fritz H, Fink E: Human keratinocyte 
 cell lines differ in the expression of the collagenolytic matrix metalloproteinases –1,  -8, and –13 and of  
 TIMP-1. Biol Chem 2000; 381: 509-16. 
Bando Y, Henderson B, Meghji S, Poole S, Harris M. Immunocytochemical localization of inflammatory 
  cytokines and vascular adhesion receptors in radicular cysts. J Oral Pathol Med 1993; 22: 221-227. 
Bannikov GA, Karelina TV, Collier IE, Marmer BL, Goldberg GL. Substrate binding of gelatinase B induces its  
 enzymatic activity in the presence of intact propeptide. J Biol Chem 2002; 277: 16022-16027. 
Balbin M, Fueyo A, Knäuper V, Pendas AM, López JM, Jiménez MG, Murphy G, López-Otín C. Collagenase 2 
(MMP-8) expression in murine tissue-remodeling process. Analysis of its potential role in postpartum 
involution of the uterus. J Biol Chem 1998; 273: 23959-23968. 
Barille S, Akhoundi C, Collette M, Mellerin MP, Rapp MJ, Harousseau JL, Bataille R, Amiot M. 
  Metalloproteinases in multiple myeloma: production of matrix metalloproteinase-9 (MMP-9), activation of 
   proMMP-2, and induction of MMP-1 by myeloma cells. Blood 1997; 90: 1649-1655. 
Barille S, Bataille R, Rapp M-J,Harousseau J-L, Amiot M. Production of metalloproteinase-7 (matrilysin) by 
 human myeloma cells and its potential involvement in metalloproteinase-2 activation. J Immunol 1999; 163: 
 5723-5728. 
Barkhordar RA. Determing the presence and origin of collagenase in human periapical lesions. J Endod 1987; 
 13: 228-232. 
Barkhordar RA, Hussain MZ,Hayashi C. Detection of interleukin 1-beta in human periapical lesions. Oral Surg 
  Oral Med Oral Pathol 1992; 73: 334-336. 
Bergenholtz G. Evidence for bacterial causation of adverse pulpal responses in resin-based dental restorations.  
 Crit Rev Oral Biol Med 2000; 11: 467-480. 
Bezerra MM, Brito GA, Ribeiro RA, Rocha FA. Low-dose doxycycline prevents inflammatory bone resorption 
  in rats.  Braz J Med Biol Res 2002; 35: 613-616. 
Birkedal-Hansen H, Moore WG, Bodden MK, Windsor LJ, Birkedal-Hansen B, DeCarlo A, Engler JA. Matrix  
 metalloproteinases: a review. Crit Rev Oral Biol Med 1993; 4: 197-250. 
Bohne W. Light and ultrastructural studies of human chronic periapical lesions. J Oral Pathol Med 1990; 19: 
  215-220. 
Bredow DCvon, Cress AE, Howard EW, Bowden GT, Nagle RB. Activation of gelatinase-tissue-inhibitors- 
 52
 of-metalloproteinase complexes by matrilysin. Biochem J 1998; 331: 965-972. 
Carter A, Merchav S, Silvian-Draxler I, Tatarsky I. The role of interleukin-1 and tumour necrosis-alpha in 
 human multiple myeloma. Br J Haematol 1990; 74: 424-431. 
Chang YC, Yang SF, Hsieh YS. Regulation of matrix metalloproteinase-2 production by cytokines 
   and pharmacological agents in human pulp cell cultures. J Endod 2001; 27: 679-682. 
Chang YC, Lai CC, Yang SF, Chan Y, Hsieh YS. Stimulation of matrix metalloproteinases by  
 black-pigmented Bacteroides in human pulp and periodontal ligament cell cultures. J Endod 2002; 28: 
  90-93. 
Cootauco CJ, Rauschenberger CR, Nauman RK. Immunocytochemical distribution of human PMN elastase and  
 cathepsin-G in dental pulp. J Dent Res 1993; 72: 1485-1490. 
Cowell S, Knäuper V, Steward M, d’Ortho MP, Stanton H, Hembry R, López-Otín C, Reynolds JJ, Murphy G.  
 Induction of matrix metalloproteinase activation cascades based on membrane-type 1matrix  
 metalloproteinase: associated activation of gelatinase A; gelatinase B and collagenase 3. Biochem J 1998;  
 331: 453-458. 
Curran S, Murray GI. Matrix metalloproteinases: molecular aspects of their roles in tumour invasion 
 and metastasis. Eur J Cancer 2000; 36: 1621-1630. 
Derenne S, Amiot M, Barilee S, Collette M, Robillard N, Berthaud P, Harousseau JL, BatailleR.  Zoledronate is 
 a potent inhibitor of myeloma cell growth and secretion of IL-6 and MMP-1 by the tumoral environment.  
 J Bone Miner Res 1999; 14: 2048-2056. 
Deryugina EI, Ratnikov B, Monosov E, Postnova TI, DiScipio R, Smith JW, Strongin AY. MT1-MMPinitiates  
activation of pro-MMP-2 and integrin ?v?3 promotes maturation of MMP-2 in breast carcinoma cells. Exp 
Cell Res 2001; 263: 209-223. 
DiGirolamo N, Visvanathan K, Lloyd A, Wakefield D. Expression of TNF-alpha by human plasma cells in  
 chronic inflammation. J Leukoc Biol 1997; 61: 667-678. 
DiGirolamo N, Tedla N, Lloyd A, Wakefield D. Expression of matrix metalloproteinases by human plasma cells  
 and B lymphocytes. Eur J Immunol  1998; 28: 1773-1784. 
Ding Y, Uitto V-J, Firth J, Salo T, Haapasalo M, Konttinen YT, Sorsa T. Modulation of host matrix  
    metallorproteinases by bacterial virulence factors relevant in human periodontal diseases. Oral Dis 1995; 1:  
    279-286. 
Ding Y, Uitto VJ, Haapasalo M, Lounatmaa K, Konttinen YT, Salo T, Grenier D, Sorsa T. Membrane 
  components of Treponema denticola trigger proteinase release from human polymorphonuclear leukocytes. J 
 Dent Res 1996; 75: 1986-1993. 
Ding Y, Haapasalo M, Kerosuo E, Lounatmaa K, Kotiranta A, Sorsa T. Release and activation of  human 
 neutrophil matrix metallo- and serine proteinases during phagocytosis of Fusobacterium nucleatum,  
    Porphyromonas gingivalis and Treponema denticola. J Clin Periodontol 1997; 24: 237-248. 
D’Ortho MP, Will H, Atkinson S, Butler G, Messent A, Gavrilovic J, Smith B, Timpl R, Zardi L, Murphy G. 
 Membrane type matrix metalloproteinases 1 and 2 exhibit broad-spectrum proteolytic capacities comparable 
 to many matrix metalloproteinases. Eur J Biochem 1997; 250: 751-757. 
Edwards DR, Beaudry PP, Laing TD, Kowal V, Leco KJ, Leco PA, Lim MS. The roles of tissue inhibitors of  
metalloproteinases in tissue remodelling and cell growth. Int J Obes Relat MetabDisord 1996; 20 (suppl 3): 
S9-S15. 
Formigli L, Orlandini S, Tonelli P, Giannelli M, Martinin M, Brandi ML, Bergamini M, Orlandini GE. 
 Osteolytic processes in human radicular cysts: morphological a biochemical results. J Oral Pathol Med 1995;  
 24: 216-220. 
Fouad AF. Moleclar mediators of Pulpal inflammation. In Hargreaves KM, Goodis HE editors. Seltzer and  
 Bender’s Dental pulp. Quintessence Publishing Co, Inc. 2002; pp 247-279. 
Freije JM, Díez-Itza I, Balbin M, Sanchez LM, Blasco R, Tolivia J, Lopez-Otin C. Molecular cloning and  
expression of collagenase-3, a novel human matrix metalloproteinase produced by breast carcinomas. J Biol  
Chem 1994; 269: 16766-16773. 
 Gendron R, Grenier D, Sorsa T, Mayrand D. Inhibition of the activities of matrix metalloproteinases -2, -8 and – 
 9 by clorhexidine. Clin Diagn Lab Immunol 1999; 6: 437-439. 
Giambernardi TA, Grant GM, Taylor GP, Hay RJ, Maher VM, McCormick JJ, Klebe RJ. Overview of matrix 
 metalloproteinases expression in cultured human cells. Matrix Biol 1998; 16: 483-496. 
Giannelli G, Falk-Marzillier J, Schiraldi O, Stetler-Stevenson WG, Quaranta V: Induction of cell migration by  
 matrix metalloprotease-2 cleavage of laminin-5. Science 1997; 277: 225-228. 
Giannelli G, Pozzi A, Stetler-Stevenson W, Gardner H, Quaranta V: Expression of  Matrix metalloprotease-2 
 cleaved laminin-5 in breast remodelling stimulated by sex steroids. Am J Pathol 1999; 154: 1193-1201. 
Gilles C, Polette M, Coraux C, Tournier JM, Meneguzzi G, Munaut C, Volders L, Rousselle P, Birembaut P, 
  Foidart JM. Contribution of MT1-MMP and of human laminin-5 ?2 chain degradation to 
 mammary epithelial cell migration. J Cell Sci 2001; 114: 2967-2976. 
 53
Goetzl EJ, Banda MJ, Leppert D. Matrix metalloproteinases in immunity. J Immunol 1996; 156: 1-4. 
Goldberg GI, Wilhelm SM, Kronberger A, Bauer EA, Grant GA, Eisen AZ. Human fibroblast collagenase.  
Complete primary structure and homology to an oncogene transformation-induced rat protein. J Biol Chem 
1986; 261: 6600-6605. 
 Goldberg GI, Marmer BL, Grant GA, Eisen AZ, Wilhelm S, He CS. Human 72-kilodalton type IV collagenase 
 forms a complex with a tissue inhibitor of metalloproteinases designated TIMP-2. Proc Natl Acad 
   Sci USA 1989; 86: 8207-8211. 
  Golub LM, Sorsa T, Lee HM, Ciancio S, Sorbi D, Ramamurthy NS, Gruber B, Salo T, Konttinen YT.  
 Doxycycline inhibits neutrophil (PMN)-type matrix metalloproteinases in human adult periodontitis  
 gingiva. J Clin Periodontol 1995; 22: 100-109. 
 Golub LM, Lee HM, Greenwald RA, Ryan ME, Sorsa T, Salo T, Giannobile WV. A matrix metalloproteinase 
inhibitor reduces bone-type collagen degradation fragments and specific collagenases in gingival crevicular 
fluid during adult periodontitis. Inflamm Res 1997; 46: 310-319. 
Golub LM, Lee HM, Ryan ME, Giannobile WV, Payne J, Sorsa T. Tetracyclines inhibit connective  
    tissue breakdown by multiple non-antimicrobial mechanisms. Adv Dent Res 1998; 12: 12-26. 
Gu Y, Lee HM, Roemer EJ, Musacchia L, Golub LM, Simon SR. Inhibition of tumor cell invasiveness 
    by chemically modified tetracyclines. Curr Med Chem 2001; 8: 261-270. 
Gutman A, Wasylyk B. The collagenase gene promoter contains a TPA and oncogne-responsive unit  
    encompassing the PEA3 and AP-1 binding sites. EMBO J 1990; 9: 2241-2246. 
Haapasalo M. Bacteroides spp. In dental root canal infections. Endod Dent Traumatol 1989; 5: 1-10. 
Haapasalo M. Käytännön juurihoito.  kerava, Finland: RT-Print; 1998. 
Hanemaaijer R, Sorsa T, KonttinenYT, Ding Y, Sutinen M, Visser H, van Hinsbergh VW, Helaakoski 
    T, Kainulainen T, Rönkä H, Tschesche H, Salo T. Matrix metalloproteinase-8 is expressed in rheumatoid   
   synovial fibroblasts and endothelial cells. Regulation by tumor necrosis factor- alpha  and doxycycline. J Biol  
    Chem 1997; 272: 31504-31509. 
Hasty  KA, Jeffrey JJ, Hibbs MS, Welgus HG. The collagen substrate specificity of human neutrophil  
 collagenase. J Biol Chem 1987; 21: 10048-10052. 
Hasty KA, Pourmotabbed TF, Goldberg GI, Thompson JP, Spinella DG, Stevens RM, Mainardi CL. Human  
neutrophil collagenase. A distinct gene product  with homology to other matrix metalloproteinases. J Biol 
Chem 1990; 265: 11421-11424. 
Hayakawa T, Yamashita K, Tanzawa K, Uchijima E, Iwata K. Growth- promoting activity of tissue inhibitor of  
metalloproteinases-1 (TIMP-1) for a wide  range of cells. A possible new growth factor in serum. FEBS Lett 
1992; 298: 29-32. 
Hayakawa T, Yamashita K, Ohuchi E, Shinagawa A.  Cell growth-promoting activity of tissue   inhibitor of  
    metalloproteinase-2 (TIMP-2). J Cell Sci 1994; 107: 2373-2379. 
Heikkilä P, Teronen O, Moilanen M, Konttinen YT,  Hanemaaijer R, laitinen M, Maisi P, van der Pluijm G,   
 Bartlett JD, Salo T, Sorsa T. Bisphosphonates inhibit stromelysin-1 (MMP-3),  matrix  metalloelastase 
(MMP-  12), collagenase-3 (MMP-13) and enamelysin (MMP-20), but not urokinase-type plasminogen 
activator, and diminish invasion and migration of human malignant and endothelial cell lines. Anticancer 
Drugs 2002; 13: 245-254. 
Heikkilä P, Teronen O, Hirn MY, Sorsa T, Tervahartiala T, Salo T, Konttinen YT, Halttunen T, Moilanen M, 
Hanemaaijer R, Laitinen M. Inhibition of matrix metalloproteinase-14 in osteosarcoma cells by clondronate. J 
Surg Res 2003; 111: 45-52. 
Hirshberg A, Sherman S, Buchner A, Dayan D. Collagen fibres in the wall of odontogenic keratocysts:  
 a study with picrosirius red and polarizing microscopy. J Oral Pathol Med 1999: 28: 410-412. 
Hoenig JF, Rordorf-Adam C, Siegmund C, Erard F. Measurement of interleukin 1 alpha and beta (IL-1alpha and  
IL-1 beta) in human cystic lesions of the jaw. Implications for the pathogenesis of radicular cysts. Bull Group 
Int Rech Sci Stomatol  Odontol 1991; 34: 67-72. 
Hofmann UB, Westphal JR, van Muijen GN, Ruiter D. Matrix metalloproteinases in human melanoma. J Invest  
 Dermatol 2000; 115: 337-344. 
Holliday LS, Welgus HG, Fliszart CJ, Veith M, Jeffrey JJ, Gluck SL. Initiation of osteoclasts bone resoption by  
 interstitial collagenase. J Biol Chem 1997; 35: 22053-220589. 
Holopainen J, Moilanen J, Sorsa T, Kivelä-Rajamäki M, Tervahartiala T, Vesaluoma M, Tervo T. Activation of 
matrix metalloproteinase-8 by membrane type 1-MMP and their expression in human tears after 
photorefractive keratectomy. Invest Ophtalmol Vis Sci 2003; 44: 2550-2556. 
Horiba N, Maekawa Y, Abe Y, Ito M, Matsumoto T, Nakamura H. Correlations between endotoxin and clinical  
 symptoms or radiolucent areas in infected root canals. Oral Surg Oral Med Oral Pathol 1991; 71: 492-495.  
Hoshino M, Nakamura Y, Sim J, Shimojo J, Isogai S. Bronchial subepithelial fibrosis and xpression of matrix  
 metalloproteinase-9 in asthmatic airway inflammation. J Allergy Clin Immunol 1998: 102: 783-788. 
Huhtala P, Chow LT, Tryggvason K. Structure of the human type IV collagenase gene. J Biol Chem 1990; 265: 
 54
 11077-11082. 
Ingman T, Tervahartiala T, Ding Y, Tschesche H,  Haerian T,Kinane DF, Konttinen YT, Sorsa T. Matrix 
metalloproteinases and their inhibitors in gingival crevicular fluid and saliva of periodontitis patients. J Clin 
Periodontol 1996; 23: 1127-1132. 
Ito A, Mukaiyama A, Itoh Y, Nagase H, Thogersen IB, Enghild JJ, SasaguriY, MoriY. Degradation of  interleukin 1  
 IL-1? by matrix metalloproteinases. J Biol Chem 1996; 271: 14657-14660. 
Jaffe ES, Harris NL, Stein H, Wardi JW. Who classification of tumours, pathology and genetics, tumour of 
 haematopoetic and lymphoid tissues. IARC-Press, Lyon, France. 2001. 
Johansson N, Airola K, Grenman R, Kariniemi AL, Saariaho-Kere U, Kähäri VM. Expression of collagenase-3  
   (matrix metalloproteinase-13) in squamous cell carcinomas of the head and neck. Am J Pathol 1997a; 151:  
    499-508.  
Johansson N, Westermarc KJ, Leppä S, Häkkinen L, Koivisto L, Lopez-Otin C, Peltonen J, Heino J, Kähäri VM.  
Collagenase 3 (Matrix metalloproteinase 13) gene expression by HaCaT keratinocytes is enhanced by tumor 
necrosis factor alpha and transforming growth factor beta. Cell Growth & Different 1997b; 8: 243-250. 
 Johansson N, Ahonen M, Kähäri VM. Matrix metalloproteinases in tumor invasion. Cell Mol Life Sci 2000; 57:  
    5-15. 
Kähäri VM, Saarialho-Kere U. Matrix metalloproteinases and their inhibitors in tumour growth and  
 invasion. Ann Med 1999; 31: 34-35. 
Kallunki P, Sainio K, Eddy R, Byers M, Kallunki T, Sariola H, Beck K, Hirvonen H, Shows TB, Tryggvason K.  
    A truncated laminin chain homologous to the B2 chain: structure, spatial expression, and chromosomal 
 assignment. J Cell Biol 1992; 119: 679-693. 
Kerr LD, Miller DB, Matrisian LM. TGF-?1 inhibition of transin/stromelysin gene expression is mediated 
 through a Fos binding sequence. Cell 1990; 61: 267-278. 
Khokha R, Waterhouse P, Yagel S, Lala PK, Overall CM, Norton G, Denhardt DT. Antisense RNA-induced 
 reduction in murine TIMP-levels confers oncogenicity on Swiss 3T3 cells. Science 1989; 243: 947-950. 
Kivelä-Rajamäki M, Teronen O, Maisi P, Husa V, Tervahartiala T, Piriä E, Salo T, Mellanen L, Sorsa T.  
Laminin -5 ?2-chain and collagenase-2 (MMP-8) in human peri-implant sulcular fluid. Clin Oral Impl Res 
2003; 14: 158-165. 
Knäuper V, López-Otín C, Smith B, Knight G, Murphy G. Biochemical characterization of human collagenase- 
 3. J Biol Chem 1996a; 271: 1544-1550. 
Knäuper V, Will H, López-Otín C, Smith B, Atkinson SJ, Stanton H, Hembry RM, Murphy G. Cellular  
 mechanism for human procollagenase-3 activation. Evidence that MT1-MMP (MMP-14) and gelatinase A  
 (MMP-2) are able to generate active enzyme. J Biol Chem 1996b; 271: 17124-17131. 
Knäuper V, Smith B, López-Otín C, Murphy G. Activation of progelatinase B (proMMP-9) by active 
 collagenase-3 (MMP-13). Eur J Biochem 1997; 248: 369-373. 
Kiili M, Cox SW, Chen HW, Wahlgren J, Maisi P, Eley BM, Salo T, SorsaT. Collagenase-8 (MMP-8) and 
    collagenase-3 (MMP-13) in adult periodontitis: molecular forms and levels in gingival crevicular fluid and  
    immunolocalization in gingival tissue. J Clin Periodontol 2002; 29: 224-232. 
Koivunen E, Arap W, Valtanen H, Rainisalo A, Medina O, Heikkilä P, Kantor C, Gahmberg C, Salo T,  
   Konttinen YT, Sorsa T, Ruoslahti E, Pasqualini R. Tumor targeting with a selective gelatinase inhibitor. Nat  
    Biotechnol 1999; 17: 768-774. 
Konttinen YT, Lindy O, Kemppinen P, Saari H, Suomalainen K, Vauhkonen M, Lindy S, Sorsa T. Collagenase  
reserves in polymorphonuclear neutrophil leukocytes from synovial fluid and peripheral blood of patients 
with rheumatoid arthritis. Matrix 1991; 11: 296-301. 
Konttinen YT, Ceponis A, Takagi M, Ainola M, Sutinen M, Sorsa T,Salo T, Ma J, Santavirta S, Seiki M. New  
 collagenolytic enzymes/cascade identified at the pannus-hard  tissue junction in rheumatoid arthritis: 
 destruction from above. Matrix Biol 1998; 17: 585-601.  
Koshikawa N, Giannelli G, Cirulli V, Miyazaki K, Quaranta V. Role of cell surface metalloprotease MT1-MMP  
 in epithelial cell migration over laminin-5. J Cell Biol 2000; 148: 3:  615-624. 
Kramer IRH. Changing views on oral disease. Proc R Soc Med 1974; 67: 271-276. 
Kramer, IRH, Pindborg JJ, Shear M. Histological typing of odontogenic tumours, 2nd ed, Berlin: Springer- 
 Verlag, 1992: 35-41. 
Kubota Y, Ninomiya T, Oka S, Takenoshita Y, Shirasuna K. Interleukin-1alpha-dependent regulation of matrix 
  metalloproteinase-9 (MMP-9) secretion and activation in the epithelial cells of odontogenic jaw cysts. J Dent  
  Res 2000; 79: 1423-1430. 
Kubota Y, Oka S, Nakagawa S, Shirasuna K. Interleukin 1-? enhances type I collagen-induced activation of 
   matrix metalloproteinase-2 in odontogenic keratocyst fibroblasts. J Dent Res 2002; 81: 23-27. 
Lanone S, Zheng T, Zhu Z, Liu W, Lee CG, Ma B, Chen Q, Homer RJ, Wang J, Rabach LA, Rabach ME, 
 Shipley JM, Shapiro SD, Senior RM, Elias JA. Overlapping and enzyme-specific contributions of matrix  
    metalloproteinases-9 and –12 in IL-13-induced inflammation and remodelling. J Clin Invest 2002; 110: 463- 
 55
    474. 
Lauta VM. Interleukin-6 and the network of several cytokines in multiple myeloma: an overview of clinical and  
    experimental data. Cytokine 2001; 16: 79-86.  
Leco KJ, Khokha R, Pavloff N, Hawkes SP, Edwards DR. Tissue inhibitor of metalloproteinase-3 (TIMP-3) is an 
   extracellular matrix-associated protein with a distinctive pattern of expression in mouse cells and tissue. J Biol  
   Chem 1994; 269: 9352-9360. 
Lerner UH. Regulation of bone metablism by the kallikrein-kinin system, the coagulation cascade, and the acute- 
    phase reactants. Oral Surg Oral Med Oral Pathol 1994; 78: 481-493. 
Lesot H, Smith AJ, Tziafas D, Begue-Kirn C, Cassidy N, Ruch JV. Biologically active molecules and dental  
   tissue repair: a comparative review of reactionary and reparative dentinogenesis with the induction of   
    odontoblast differentiation in vitro. Cells Mater 1994; 4: 199-218. 
Li TJ, Browne RM, Matthews JB. Quantification of PCNA+ cells within odontogenic jaw cyst epithelium. J 
    Oral Pathol Med 1994; 23: 184-189. 
Li T, Browne RM, Matthes JB. Immunocytochemical expression of growth factors by odontogenic jaw cysts. 
   Mol Pathol 1997; 50: 21-27. 
Lin SK, Chiang CP, Hong CY, Lin CP, Lan WH, Hsieh CC, Kuo MY. Immunolocalization of interstitial  
   collagenase (MMP-1) and tissue inhibitor of metalloproteinases-1 (TIMP-1) in radicular cysts. J Oral Pathol  
   Med 1997; 26: 458-463. 
Lin SK, Wang CC, Huang S, Lee JJ, Chiang CP, Lan WH, Hong CY. Induction of Dental pulp fibroblast matrix 
 metalloproteinases-1 and tissue inhibitor of metalloproteinases-1 gene expression by interleukin-1? and tumor  
   necrosis factor-? through a prostaglandin-dependent pathway. J Endod 2001; 27: 185-189. 
Lindy O, Konttinen YT, Sorsa T, Ding Y, Santavirta S, Ceponis A, López-Otín C. Matrix metalloproteinase 13 
   (collagenase 3) in human rheumatoid synovium. Arthritis Rheum 1997; 40: 1391-1399. 
Liu Y, Ryan M, Lee H-M, Sorsa T, Salo T, Tjäderhane L, Walker S, Golub L. A chemically modified 
 tetracycline (CMT-3) inhibits a metalloproteinase of C. Albicans. J Dent Res (Spec Iss A) 2002: 81: A-284. 
Llano E, Pendas AM, Knäuper V, Sorsa T, Salo T, Salido E, Murphy G, Simmer JP, Bartlett JD, Lopez-Otin C. 
Identification and structural and functional characterization of human enamelysin (MMP-20). Biochemistry 
1997; 36: 15101-15108. 
Llavaneras A, Golub LM, Rifkin BR, Heikkila P, Sorsa T, Teronen O, Salo T, Liu Y, Ryan ME, Ramamurthy 
 NS. CMT-8/clondronate combination therapy synertically inhibits alveolar bone loss in LPS-induced  
   periodontitis. Ann N Y Acad Sci 1999; 878: 671-674. 
Llavaneras A, Ramamurthy NS, Heikkilä P, Teronen O, Salo T, Rifkin BR, Ryan ME, Golub LM, Sorsa T.  A 
 combination of a chemically modified doxycycline and a bisphosphonate synergistically inhibits endotoxin-  
   induced periodontal breakdown in rats. J Periodontol 2001; 72: 1069-1077. 
Lohi J. Laminin-5 in the progression of carcinomas. Int J Cancer 2001; 94: 763-767. 
Lohi J, Wilson CL, Roby JD, Parks WC. Epilysin, a novel human matrix metalloproteinase (MMP-28) expressed 
    in testis and keratinocytes and in response to injury. J Biol Chem 2001; 276: 10134-10144. 
Lokeshwar BL, Selzer MG, Zhu BQ, Block NL, Golub LM. Inhibition of cell proliferation, invasion, tumor  
 growth and metstasis by an oral non-antimicrobial tetracycline analog (COL-3) in a metastatic prostate cancer  
   model. Int J Cancer 2002; 98: 297-309. 
Lu HX, Xiao MZ, Niu XY, Guo XM, Zhao SL, Wang HG, Guo HY. Effect of IL-1ra on human dental pulp cells 
 and  pulpal inflammation. Int Endod J 2002; 35: 807-811. 
Lukinmaa PL, Vaahtokari A, Vainio S, Thesleff I. Expression of the type I collagen pro-alfa 2 chain mRNA in 
    adult human permanent teeth as revealed by in situ hybridization. J Dent Res 1992; 71; 36-42. 
Lukinmaa PL, Vaahtokari A, Vainio S, Sandberg M, Waltimo J, Thesleff I. Transient expression of type III 
    collagen by odontoblasts: developmental changes in the distribution of pro-alpha 1(III) and pro-alpha 1(I) 
   collagen mRNAs in dental tissues. Matrix 1993; 13: 503-515. 
Lukkonen A, Sorsa T, Salo T, Tervahartiala T, Koivunen E, Golub L, Simon S, Stenman U-H. Down-regulation 
   of  trypsinogen-2 expression by chemically modified tetracyclines: association with reduced cancer cell  
   migration. Int J Cancer 2000; 86: 577-581. 
Mäkelä M, Larjava H, Pirilä E, Maisi P, Salo T, Sorsa T, Uitto VJ. Matrix metalloproteinase-2 (gelatinase-A) is  
   related to migration of keratinocytes. Exp Cell Res 1999; 251: 67-78. 
Mäntylä P, Kinane D, Luoto S, Tikanoja S, Sorsa T . MMP (matrix metalloproteinase) –8 in monitoring  periodontal 
     health and disease from gingival crevicular fluid (GCF). J Clin Periodontol 2000; 27 (suppl 1): 97. 
Mäntylä P, Stenman M, Kinane D, Tikanoja S, Luoto H, Salo T, Sorsa T. Gingival grevicular fluid collagenase-2  
    (MMP-8) test stick for chair-side monitoring of periodontitis. J Periodontal Res 2003; 38: 436-439. 
Marchenko GN, Ratnikov BI, Rozanov DV, Godzik A, Deryugina EI, Strongin AY. Characterization of matrix 
   metalloproteinase-26, a novel metalloproteinase widely expressed in cancer cells of epithelial origin. Biochem J  
   2001; 356: 705-718. 
Marchenko GN, Strongin AY.  MMP-28, a new human matrix metalloproteinase with an unusual cysteine- 
 56
 switch  sequence is widely expressed in tumors. Gene 2001; 265: 87-93. 
Marton IJ, Kiss C. Protective and destructive immune reactions in apical periodontitis. Oral Microbiol Immunol 
   2000; 15: 139-150. 
Matsuo T, Nakanishi T, Ebisu S. Immunoglobulins in periapical exudates of infected root canals: correlations  
  with the clinical findings of the involved teeth. Endod Dent Traumatol 1995; 11: 95-99. 
Matthes T, Werner-Favre C, Zubler RH. Cytokine expression and regulation of human plasma cells:  
    disappearance of interleukin-10 and persistence of transforming growth factor-?1. Eur J Immunol 1995; 25:  
    508-512. 
Matthews JB, Mason GI, Browne RM. Epithelial cell markers and proliferating cells in odontogenic jaw cysts. 
    J Pathol 1988; 156: 283-290. 
 Mautino G, Oliver N, Chanez P, Bousquet J, Capony F. Increased release of matrix metalloproteinase-9 in  
 bronchoalveolar lavage fluid and by alveolar macrophages of asthmatics. Am J Respir Cell Mol Biol 1997; 
 17: 583-591. 
McClanahan SB, Turner DW, Kaminski EJ, Osetek EM, Heuer M. Natural modifiers of the inflammatory 
    process in the human dental pulp. J Endod 1991; 17: 589-593. 
Meikle MC, Bord S, Hembry RM, Comston J, Croucher PI, Reynolds JJ. Human osteoblasts in culture  
synthesize collagenase and other matrix metalloproteinases in response to osteotropic hormones and 
cytokines. J Cell Sci 1992; 103: 1093-1099. 
Meghji S, Henderson B, Bando Y, Harris M. Interlukin-1: the principal osteolytic cytokine produced by  
   keratocysts. Arch Oral Biol 1992; 37: 935-943. 
Meghji S, Qureshi W, Henderson B, Harris M. The role of endotoxin and cytokines in the pathogenesis of  
   odontogenic cysts. Arch Oral Biol  1996; 41: 523-31. 
Merville P, Dechanet J, Grouard G, Durand I, Banchereau J. T cell-induced B cell blasts differentiate into plasma  
 cells when cultured on bone marrow stroma with IL-3 and IL-10. Int Immunol 1995; 7: 635-643. 
Metzger Z. Macrophages in periapical lesions. Endod Dent Traumatol 2000; 16: 1-8. 
Michaelis J, Vissers MC, Winterbourn CC. Human neutrophil collagenase cleaves ?1-antirypsin. Biochem J 1990; 
     270: 809-814. 
Miller GA, DeMayo T, Hutter JW. Production of interleukin-1 by polymorphonuclear leucocytes resident in   
   periradicular tissue. J Endod 1996; 22: 346-351. 
Mirastschijski U, Impola U, Jahkola T, Karlsmark T, Agren MS, Saarialho-Kere U. Ectopic localization  
    of matrix metalloproteinase-9 in chronic cutaneous wounds. Hum Pathol 2002; 33: 355-364. 
Mitchell PG, Magna HA, Reeves LM, Lopresti-Morrow LL, Yocum SA, Rosner PJ, Geoghegan KF, Hambor JE. 
    Cloning, expression, and type II collagenolytic activity of matrix metalloproteinase-13 from human osteoarthritic  
    cartilage. J Clin Invest 1996; 97: 761-768. 
Miyauchi M, Takata T, Ito H, Ogawa I, Kobayashi J, Nikai H, Ijuhin N. Immunohistochemical detection of  
prostaglandins E2, F2?, and 6-ketoprostaglandin F1? in experimentally induced periapical inflammatory lesions 
in rats. J Endod 1996; 22: 635-637. 
Moilanen M,Sorsa T, Stenman M, Nyberg P, Lindy O, Vesterinen J, Paju A, Konttinen YT, StenmanU-H, Salo 
 T. Tumor-associated trypsinogen-2 (trypsinogen-2) activates procollagenases (MMP-1, -8,-13) and 
 stromelysin-1 (MMP-3) and degrades type I collagen. Biochemistry 2003; 42: 5414-5420. 
Morand MA, Schilder H, Blondin J, Stone PJ, Franzblau C. Collagenolytic and elastinolytic activities from  
 diseased human dental pulps. J Endod 1981; 7: 156-160. 
Myoung H, Hong S-P, Hong S-D, Lee J-I, Lim C-Y, Choung P-H, Lee J-H, Choi J-Y, Seo B-M, Kim M-J.  
Odontogenic keratocyst: Review of 256 cases for recurrence and clinicopathologic parameters. Oral Surg 
Oral Med Oral Pathol Oral Radiol Endod 2001; 91: 328-333. 
Nakanishi T, Matsuo T, Ebisu S. Quantitative analysis of immunoglobulins and inflammatory factors in human 
    pulpal blood from exposed pulps. J Endod 1995; 21: 999-1003. 
Nakano A, Tani E, Miyazaki K, Furuyama J, Matsumoto T. Expression of matrilysin and stromelysin in human 
    glioma cells. Biochem Biophys Res Commun 1993; 192: 237-244. 
Nakata K, Yamasaki M, Iwata T, Suzuki K, Nakane A, Nakamura H. Anaerobic bacterial extracts influence  
    production of matrix metallopoteinases and their inhibitors by human dental pulp cells. J Endod 2000; 26: 410- 
    413. 
Neville BW, Damm DD, Allen CM, Bouquot JE. Oral & Maxillofacial Pathology. Philadelphia,  USA: WB Saunders  
 Co 2002; pp 107-136, 589-601. 
 Nisengard R, Newman M. Oral microbiology and immunology, second edition. Philadelphia, USA: W.B.  
 Saunders Co  1994; pp 8-10. 
Nyberg P, Moilanen M, Paju A, Sarin A, Stenman UH, Sorsa T, Salo T. MMP-9 activation by tumor trypsin-2  
 enhances in vivo invasion of human tongue carsinoma cells. J Dent Res 2002; 81: 831-835. 
O’Boskey FJ Jr, Panagakos F. Cytokines stimulate matteix metalloproteinase production by human pulp  
 cells during long-term culture. J Endod 1998; 24: 7-10. 
 57
Okiji T.  Pulp as a connective tissue.  In: Hargreaves KM, Goodis HE editors. Seltzer and Bender’s Dental pulp.  
 Quintessence Publishing Co, Inc. 2002; pp 95-122. 
  Overall CM, Wrana JL, Sodek J. Transcriptional and post-transcriptional regulation of 72-kDa elatinase/type 
IV collagenase by transforming growth factor-?1 in human fibroblasts. Comparisons with collagenase and 
tissue inhibitor of matrix metalloproteinase gene expression. J Biol Chem 1991; 266: 14064-14071. 
Palosaari H, Tasanen K, Risteli J, Larmas M, Salo T, Tjäderhane L. Baseline expression and effect of TGF-beta1 
 on type I and III collagen mRNA and protein synthesis in human odontoblast and pulp cells in vitro. Calcif  
   Tissue Int 2001; 68: 122-129. 
Palosaari H, Ding Y, Larmas M, Sorsa T, Bartlett JD, Salo T, Tjäderhane L. Regulatio and interactions of MT1- 
   MMP and MMP-20 in human odontoblasts and pulp tissue in vitro. J Dent Res 2002; 81: 354-359. 
Panagakos FS, O'Boskey JF Jr, Rodriguez E. Regulation of pulp cell matrix metalloproteinase production by  
   cytokines and lipopolysaccharides. J Endod 1996; 22: 358-361. 
Patel V, Aldridge K, Ensley JF, Odell E, Boyd A, Jones J, Gutkind JS, Yeudall WA. Laminin-?2 
 overexpression in head-and-neck squamous cell carsinoma. Int J Cancer 2002; 99: 583-588. 
Pattengale PK. Role of interleukin-6 in the pathogenesis of murine plasmacytoma and human multiple 
 myeloma. Am J Pathol 1997; 151: 647-649. 
Pei D, Weiss SJ. Furin-dependent intracellular activation of the human stromelysin-3 zymogen. Nature 1995;
  375: 244-247. 
   Peled ZM, Phelps ED, Updike DL, Chang J,Krummel TM, Howard EW, Longaker MT. Matrix metalloproteinases 
and the ntogeny of scarless repair: The other side of the wound healing balance. Plast Reconst Surg 2002; 
110: 801-811. 
   Piattelli A, Artese L, Rosini S, Quaranta M, Musiani P. Immune cells in periapical granuloma: morphological
 and immunohistochemical characterization. J Endod 1991; 17: 26-29. 
   Piattelli A, Fioroni M, Santinelli A, Rubini C. P53 protein expression in odontogenic cysts. J Endod 2001; 27: 
  459-461. 
   Pirilä E, Ramamurthy N, Maisi P, WcClain S, Kucine A, Wahlgren J, Golub L, Salo T, Sorsa T. Wound  
healing in ovariectomized rats. Effects of chemically modified tetracycline (CMT-8) and estrogen on matrix 
metalloproteinases –8, -13 and type I collagen expression. Curr Med Chem 2001a; 7: 281-294. 
   Pirilä E, Maisi P, Salo T, Koivunen E, Sorsa T. In vivo localization of gelatinases (MMP-2 and MMP-9) by in  
 situ zymography with a selective gelatinase inhibitor. Biochem Biophys Res Commun 2001b; 287: 766-774. 
   Pirilä E, Sharabi A, Salo T, Quaranta V, Tu H, Heljasvaara R, Koshikawa N, Sorsa T, Maisi P. Matrix  
metalloproteinases process laminin-5 ?2-chain and regulate epithelial cell migration. Biochem Biophys Res 
Commun 2003; 303: 1012-1017. 
   Poulsom R, Pignatelli M, Stetler-Stevenson WG, Liotta LA, Wright PA, Jeffery RE, Longcroft JM, Rogers L, 
Stamp GW. Stromal expression of 72-kda type IV collagenase (MMP-2) and TIMP-2 mRNAs in colonrectal 
neoplasia. Am J Pathol 1992; 141: 389-396. 
    Prikk K, Maisi P, Pirilä E, Sepper R, Salo T, Wahlgren J. Sorsa T. In vivo collagenase-2 (MMP-8) 
 expression by human bronchial epithelial cells and monocytes/macrophages in bronchiectasis. J Pathol 2001;  
 194: 232-238. 
Prikk K, Maisi P, Pirilä E, Reintam MA, Salo T, Sorsa T, Sepper R. Airway obstruction correlates with  
 collagenase-2 (MMP-8) expression and activation in bronchial asthma. Lab Invest 2002; 82:1535-1545. 
Pulkkinen L, Christiano AM, Airenne T, Haakana H, Tryggvason K, Uitto J. Mutations in the ?2 chain gene- 
(LAMC2) of kalinin/laminin 5 in the junctional forms of epidermolysis bullosa. Nature Genet 1994; 6: 293-
297. 
Ramamurthy NS, Rifkin BR, Greenwald RA, Xu JW, Liu Y, Turner G, Golub LM, Vernillo AT. Inhibition of  
matrix metalloproteinase-mediated periodontal bone loss in rats: a comparison of 6 chemically modifies 
tetracyclines. J Periodontol 2002; 73: 726-734. 
Ravanti L, Häkkinen L, Larjava H, Saarialho-Kere, Foschi M, Han J, KähäriVM. Transforming growth factor-? 
induces collagenase-3 expression by human gingival fibroblasts via p38 mitogen-activated protein kinase. J 
Biol Chem 1999; 274: 37292-37300. 
Regezi JA. Odontogenic cysts, odontogenic tumors, fibroosseus, and giant cell lesions of the jaws. Mod 
 Pathol 2002; 15: 331-341. 
Reponen P, Sahlberg C, Munaut C, Thessleff I, Tryggvason K.High expression of 92 -kD type IV collagenase 
 (gelatinase B) in the osteoclast lineage during mouse development. J Cell Biol 1994; 124: 1091-1102. 
Ria R, Vacca A, Ribatti D, Di Raimondo F, Merchionne F, Dammacco F. ?V?3 integrin engagement enhances
 cell invasiveness in human multiple myeloma. Haematologica 2002; 87: 836-845. 
Rifas L, Halstead LR, Peck WA, Avioli LV, Welgus HG: Human osteoblasts  in vitro secrete tissue inhibitor of  
metalloproteinases and gelatinase but not interstitial collagenase as major products. J Clin Invest 1989; 84: 
692-694. 
 Ross MH, Reith EJ, Romrell LJ. Histology: a text and atlas, 2nd ed. Baltimore, MD: Williams and Wilkins cop, 
 58
 1989; 309-311. 
Rousset F, Peyrol S, Garcia E, Vezzio N, Andujar M, Grimaud JA, Banchereau J. Long-term cultured 
CD40-activated B lymphocytes differentiate into plasma cells in response to IL-10 but not IL-4. Int Immunol 
1995; 7: 1243-1253. 
Rousselle P, Keene DR, Ruggiero F,Champliaud MF, Rest M, Burgeson RE. Laminin 5 binds to the NC- 
 1 domain of type VII collagen. J Cell Biol 1997; 138: 719-728. 
Saarialho-Kere UK, Chang ES, Welgus HG, Parks WC. Distinct localization of collagenase and tissue inhibitor  
of metalloproteinases expression in wound healing associated with ulcerative pyogenic granuloma. J Clin 
Invest 1992; 90: 1952-1957. 
Saarialho-Kere UK, Welgus HG, Parks WC. Distinct mechanisms regulate interstitial collagenase and 92-kDa 
gelatinase expression in human monocytic-like cells exposed to bacterial endotoxin. J Biol Chem 1993; 268: 
17354-17361. 
Saarialho-Kere UK, Vaalamo M, Airola K, Niemi KM, Oikarinen AI, Parks WC. Interstitial collagenase is 
expressed by keratinocytes that are actively involved in reepithelialization in blistering skin diseases. J Invest 
Dermatol 1995; 104: 982-988. 
Salo S, Haakana H, Kontusaari S, Hujanen E, Kallunki T, Tryggvason K. Laminin-5 promotes adhesion and  
migration of  epithelial cells: identification of a migration-related element in the ?2 chain gene (LAMC2) with 
activity in transgenic mice. Matrix Biol 1999; 18: 197-210. 
Salo T, Liotta LA, Tryggvason K. Purification and characterization of a murine basement membrane collagen- 
 degrading enzyme secreted by metastatic tumor cells. J Biol Chem 1983; 258: 3058-63. 
Salo T, Lyons JG, Rahemtulla F, Birkedal-Hansen H, Larjava H. Transforming growth factor-?1 up-regulates 
 type IV collagenase expression in cultured human keratinocytes. J Biol Chem 1991; 266: 11436-11441. 
Sati HI, Apperley JF, Greaves M, Lawry J,Gooding R, Russell RG, Croucher PI.  Interleukin-6 is expressed by  
 plasma cells from patients with multiple myeloma and  monoclonal gammopathy of undetermined 
 significance. Br J Haematol 1998; 101: 287-295. 
Schönbeck U, Mach F, Libby P. Generation of biologically active IL-1 beta by matrix metalloproteinases: a  
 novel caspase-1-independent pathway of IL-1 beta processing. J Immunol 1998; 161: 3340-3346. 
Shear M. The aggressive nature of the odontogenic keratocyst: is it a bening cystic neoplasm? Part1. 
  Clinical and early experimental evidence of aggressive behaviour. Oral Oncol 2002a; 38: 219-226. 
Shear M. The aggressive nature of the odontogenic keratocyst: is it a benign cystic neoplasm? Part 2. 
  Proliferation and genetic studies. Oral Oncol 2002b; 38: 323-331. 
Shear M. The aggressive nature of the odontogenic keratocyst: is it a benign cystic neoplasm? Part 3. 
 Immunocytochemistry of cytokeratin and other epithelial cell markers. Oral Oncol 2002c; 38: 407-415. 
Shin SJ, Lee JI, Baek SH, Lim SS. Tissue levels of matrix metalloproteinases in pulps and periapical 
 lesions. J Endod  2002; 28: 313-315. 
Skyldberg B, Salo S, Eriksson E, Aspenblad U, Moberger B, Tryggvason K, Auer G. Laminin-5 as a 
 marker of invasiveness in cervical lesions. J Natl Cancer Inst 1999; 91: 1882-1887. 
Soini Y, Hurskainen T, Höyhtyä M, Oikarinen A, Autio-Harmainen H. 72 KD and 92 KD type IV collagenase,  
type IV collagen, and laminin mRNAs in breast cancer: a study by in situ hybridization. J Histochem 
Cytochem 1994; 42: 945-951. 
 Soini Y, Määttä M, Salo S, Tryggvason K, Autio-Harmainen H. Expression of the laminin ?2 chain in pancreatic  
 adenocarsinoma. J Pathol 1996; 180: 290-294. 
 Soini Y, Satta J, Määttä M, Autio-Harmainen H. Expression of MMP2, MMP9, MT1-MMP, TIMP1, and TIMP2 
 mRNA in valvular lesions of the heart. J Pathol 2001; 194: 225-231. 
Sorsa T, Ylipaavalniemi P, Suomalainen K, Vauhkonen M, Lindy S. Type-specific degradation of interstitial 
 collagens by human keratocyst wall collagenase. Med Sci Res 1988; 16: 1189-1190. 
Sorsa T, Suomalainen K, Helenius J, Lindy S, Saari H, Konttinen YT, Uitto VJ. Periodontal disease. 
 (A letter). New Engl J Med 1990; 323: 133-135. 
Sorsa T, Ingman T, Suomalainen K, Haapasalo M, Konttinen YT, Lindy O, Saari H, Uitto VJ. Identification of  
proteases fom periodontopathogenic bacteria as activators of latent human neutrophil and fibroblast-type 
interstitial collagenases. Infect immun 1992; 60: 4491-4495. 
Sorsa T, Ding Y, Salo T, Lauhio A, Teronen O, Ingman T, Ohtani H, Andoh N, Takeha S, KonttinenYT. Effects  
of tetracyclines on neutrophil, gingival, and salivary collagenases. A functional and western-blot assessment 
with special reference to their cellular sources in periodontal diseases. Ann N Y Acad Sci 1994; 732: 112-131. 
Sorsa T, Ding Y, Ingman T, Salo T, Westerlund U, Haapasalo M, Tschesche H, Konttinen YT. Cellular source, 
 activation and inhibition of dental plaque collagenase. J Clin Periodontol 1995; 22: 709-717. 
Sorsa T, Salo T, Koivunen E, Tyynelä J, Konttinen YT, Bergmann U, Tuuttila A, Niemi E, Teronen O, Heikkilä 
 P, Tschesche  H, Leinonen J, Osman S, Stenman UH. Activation of type IV procollagenases by human  
 tumor-associated trypsin-2. J Biol Chem 1997; 272: 21067-21074. 
Sorsa T, Ramamurthy NS, Vernillo AT, Zhang X, Konttinen YT, Rifkin BR, Golub LM. Functional sites of 
 59
 chemically modified tetracyclines: inhibition of the oxidative activation of human neutrophil and chicken 
 osteoclast pro-matrix metalloproteinases. J Rheumatol 1998; 15: 975-982. 
Sorsa T, Mäntylä P, Rönkä H, Kallio P, Kallis GB, Lundqvist C, Kinane DF, Salo T, Golub LM,Teronen O, 
 Tikanoja S.  Scientific basis of a matrix metalloproteinase-8 specific chair-side test for monitoring  
 periodontal and peri-implant health and disease. Ann N Y Acad Sci 1999; 878: 130-140. 
Stashenko P. The role of immune cytokines in the pathogenesis of periapical lesions. Endod Dent Traumatol  
 1990; 6: 89-96. 
Sternlicht MD, Werb Z. How matrix metalloproteinases regulate cell behaviour. Annu Rev Cell Dev Biol  
 2001;  17: 463-516. 
Stetler-Stevenson WG, Kruntzsch HC, Liotta LA. Tissue inhibitor of metalloproteinase (TIMP-2). A new  
 member of the metalloproteinase inhibitor family. J Biol Chem 1989; 264: 17374-17378. 
Stetler-Stevenson WG. Type IV collagenases in tumor invasion and metastasis. Cancer Metastasis Rev 1990; 9: 
  289-303. 
Stetler-Stevenson M, Mansoor A, Lim M, Fukushima P, Kehrl J, Marti G, Ptaszynski K, Wang J, Stetler- 
Stevenson WG. Expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in 
reactive and neoplastic lymphoid cells. Blood 1997; 89: 1708-1715. 
Stolow MA, Bauzon DD, Li J, Sedgwick T, Liang VC, Sang QA, Shi YB. Identification and characterization of a  
novel collagenase in Xenopus laevis: possible roles during frog development. Mol Biol Cell 1996; 7: 1471-
1483. 
Ståhle-Bäckdahl M, Sandstedt B, Bruce K, Lindahl A, Jiménez MG, Vega JA, Lopéz-Otín C. Collagenase-3 
(MMP-13) is expressed during human fetal ossification and re-expressed in postnatal bone remodeling and in 
rheumatoid arthritis. Lab Invest 1997; 76: 717-728. 
Sulkala M, Wahlgren J, Larmas M, Sorsa T, Teronen O, Salo T, Tjaderhane L. The effect of MMP activity and  
 caries progression in rats. J Dent Res 2001; 80: 1545-1549. 
Sulkala M, Larmas M, Sorsa T, Salo T, Tjäderhane L. The localization of matrix metalloproteinase-20 (MMP- 
 20, enamelysin) in mature hyman teeth. J Dent Res 2002; 81: 603-607. 
Sutinen M. Expression of MMP-2 and MMP-9 in mucocutaneous and bone lesions.Acta Universitas  
 Dissertation. Oulu: University of Oulu, Finland; 1998; pp 64-66. 
Sutinen M, Kainulainen T, Hurskainen T, Vesterlund E, Alexander JP, Overall CM, Sorsa T, Salo T.  
Expression of matrix metalloproteinases (MMP-1 and -2) and their inhibitors (TIMP-1, -2and -3) in oral 
lichen planus, dysplasia, squamous cell carsinoma and lymph node metastasis. Br J Cancer 1998; 77: 2239-
2245. 
Takahashi K. Changes in the pulpal vasculature during inflammation. J Endod 1990; 16: 92-97. 
Takahashi K, MacDonald DG, Kinane DF. Analysis of immunoglobulin-synthetizing cells in human dental 
 periapical lesions by in situ hybridization and immunohistochemistry. J  Oral Pathol Med 1996; 25: 331-335. 
Takahashi K. Microbiological, pathological, inflammatory, immunological and molecular biological  
 aspects of    periradicular disease. Int Endod J 1998; 31: 311-325. 
Tamura M, Nagaoka S, Kawagoe M. Interleukin-1 alpha stimulates interstitial collagenase gene expression in 
 human dental pulp fibroblast. J Endod 1996; 22: 240-243. 
Teronen O, Salo T, Konttinen YT, Rifkin B, Vernillo A, Ramamurthy NS, Kjeldsen L, Borregaard N,  
Hietanen J, Sorsa T.  Identification and characterization of gelatinases/type IV collagenases in jaw cysts. J Oral 
Pathol Med 1995a; 24: 78-84. 
Teronen O, Salo T, Laitinen J, Tornwall J, Ylipaavalniemi P, Konttinen YT, Hietanen J, Sorsa T. Characterization of  
 interstitial collagenases in jaw cyst wall. Eur J Oral Sci 1995b; 103: 141-147. 
Teronen O, Konttinen YT, Lindqvist C, Salo T, Ingman T, Lauhio A, Ding Y, Santavirta S, Valleala H, Sorsa T.  
Inhibition of matrix metalloproteinase-1 by dichloromethylene bisphosphonate (clodronate). Calcif Tissue Int 
1997; 61: 59-61. 
Teronen O, Heikkilä P, Konttinen YT, Laitinen M, Salo T, Hanemaaijer R, Teronen A, Maisi P, Sorsa T.  
 MMP inhibition and downregulation by bisphosphonates. Ann N Y Acad Sci 1999; 30: 453-465. 
Teronen O, Laitinen M, Salo T, Hanemaaijer R, Heikkilä P, Konttinen YT, Sorsa T. Inhibition of matrix 
metalloproteinases by bisphosphonates may in part explain their effects in the treatment of multiple myeloma. 
Blood 2000; 96: 4006-4007. 
Tervahartiala T, Pirilä E, Ceponis A, Maisi P, Salo T, Tuter G, Kallio P, Törnwall J, Srinivas R,Konttinen YT,  
Sorsa T. The in vivo expression of the collagenolytic matrix metalloproteinases (MMP-2, -8, -13, and -14) and 
matrilysin (MMP-7) in adult and localized juvenile periodontitis. J Dent Res 2000; 79: 1969-1977. 
Thomas GJ, Lewis MP, Hart IR, Marshall JF, Speight PM. ?V?6integrin promotes invasion of squamous 
 carcinoma cells through up-regulation of matrix metalloproteinase-9. Int J Cancer 2001; 92: 641-650. 
Thomas P, Khokha R, Shepherd FA, Feld R, Tsao MS. Differential expression of matrix 
 metalloproteinase and their inhibitors in non-small cell lung cancer. J Pathol 2000; 190: 150-156. 
Tjäderhane L, Salo T, Larjava H, Larmas M, Overall CM. A novel organ culture method to study the function of  
 60
human odontoblasts in vitro: gelatinase expression by odontoblasts is differentially regulated by TGF-beta1. J 
Dent Res 1998; 77: 1486-1496. 
Tjäderhane L, Sulkala M, Sorsa T, Teronen O, Larmas M, Salo T. The effect of MMP inhibitor Metastat? on 
 fissure caries progression in rats. Ann N Y Acad Sci 1999; 878: 686-688. 
Tjäderhane L, Palosaari H, Wahlgren J, Larmas M, Sorsa T, Salo T. Human odontoblast culture method: the 
 expression of collagen and matrix metalloproteinases (MMPs). Adv Dent Res 2001; 15: 55-58. 
Torres JO, Torabinejad M, Matiz RA, Mantilla EG. Presence of secretory IgA in human periapical lesions. J  
 Endod 1994; 20: 87-89. 
Tryggvason K. The laminin family. Curr Opin Cell Biol 1993; 5:  877-882. 
Tryggvason K, Höyhtyä M, Pyke C. Type IV collagenases in invasive tumors. Breast Cancer Res Treat 1993; 
 24: 209-218. 
Uitto VJ, Airola K, Vaalamo M, Johansson N, Putnins EE, Firth JD, Salonen J, Lopez-Otin C, Saariaho-Kere U, 
Kähäri VM. Collagenase-3 (Matrix metalloproteinase-13) expression is induced in oral mucosal epithelium 
during chronic inflammation. Am J Pathol 1998; 152: 1489-1499. 
Uitto V-J, Overall C, McCulloch C. Proteolytic host cell enzymes in gingival crevice fluid. Periodontol 2000. 
 2003; 31: 77-104. 
Uria JA, Balbin M, López JM, Alvarez J, Vizoso F, Takigawa M, López-Otín C. Collagenase-3 (MMP-13) 
expression in chondrosarcoma cells and its regulation by basic fibroblast growth factor. Am J Pathol 1998; 
153: 91-101. 
Vaalamo M, Weckroth M, Puolakkainen P, Kere J, Saarinen P, Lauharanta J, Saarialho-Kere UK. Patterns of  
 matrix metalloproteinase and TIMP-1 expression in chronic and normally healing human cutaneous wounds. 
 Br J Dermatol 1996; 135: 52-59. 
Vaalamo M, Mattila L, Johansson N,  Kariniemi AL,Karjalainen-Lindsberg ML, Kahäri VM, Saarialho-Kere U.  
Distinct populations of stromal cells express collagenase-3 (MMP-13) and collagenase-1 (MMP-1) in chronic 
ulcers but not in normally healing wounds. J Invest Dermatol 1997; 109: 96-101. 
Väänänen A, Srinivas R, Parikka M, Palosaari H, Bartlett JD, Iwata K, Grenman R, Stenman UH, SorsaT, Salo T. 
  Expression and regulation of  MMP-20 in human tonque carcinoma cells. J Dent Res 2001; 80: 1884-1889. 
    Vacca A, Ribatti D, Presta M, Minischetti M, Iurlaro M, Ria R, Albini A, Bussolino F, Dammacco F.  
Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion 
parallel progression of human multiple myeloma. Blood 1999; 93: 3064-3073. 
Vaes G, Delaissé JM, Eeckhout Y. Relative roles of collagenase and lysosomal cysteine-proteinases  in bone  
 resorption. Matrix  1992; 1 (suppl): 383-388. 
Vartio T, Vaheri A: A gelatin-binding 70,000-dalton glycoprotein synthetized distinctly from fibronectin by  
 normal and malignant adherent cells. J Biol Chem 1981; 256: 13085-13090. 
Vartio T, Hovi T, Vaheri A. Human macrophages synthesize and secrete a major 95,000-dalton gelatin-binding  
 protein distinct from fibronectin. J Biol Chem 1982; 257: 8862-8866. 
Vihinen P and Kähäri VM. Matrix metallorpoteinases in cancer: prognostic markers and therapeutic targets. Int J  
 Cancer 2002; 99: 157-166. 
Vu TH, Werb Z. Matrix metalloproteinases: effectors of development and normal physiology. Genes &  
 Development 2000; 14: 2123-2133. 
Walker KE, Lappin DF, Takahashi K, Hope J, Macdonald DG,Kinane DF. Cytokine expression in periapical  
 granulation tissue as assessed by immunohistochemistry. Eur J Oral Sci 2000; 108: 195-201. 
Walton RE, Torabinejad M. Principles and practice in endodontics. WB Saunders, Philadelphia, USA . 1996. 
Wernert N, Raes MB, Lassalle P, Dehouck MP, Gosselin B, Vandenbunder B, Stehelin D. C-ets 1 protooncogene is  
a transcription factor expressed in endothelial cells during tumor vascularization and other forms of angiogenesis 
in humans. Am J Pathol 1992; 140: 547-557. 
Westerlund U, Ingman T, Lukinmaa P-L, Salo T, Kjeldsen L, Borregaard N, Tjäderhane L, Konttinen YT, Sorsa  
T. Human Neutrophil gelatinase an associated lipocalin in adult and localized juvenile periodontitis. J Dent 
Res 1996; 75: 1553-1563. 
Wucherpfennig AL, Li YP, Stetler-Stevenson WG, Rosenberg AE, Stashenko P. Expression of 92kD type IV 
 collagenase/gelatinase B in human osteoclasts. J Bone Miner Res 1994; 9: 549-55 
Ylipaavalniemi P. Proteins in jaw cysts. Dissertation. Helsinki: University of Helsinki. 1978. 
 
 
